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ABSTRACT 
 
Angiogenesis is defined as growth of new blood vessels from pre-existing ones 
and occurs during normal physiological development as well as pathological conditions 
like cancer. During angiogenesis, normally quiescent endothelial cells (ECs) are 
activated in response to external pro-angiogenic cues and undergo rapid morphogenic 
changes such as proliferation, migration, invasion, and lumen formation to extend new 
sprouts into surrounding three-dimensional (3D) matrix. To better understand angiogenic 
regulation, we utilized an in vitro model wherein sphingosine 1-phosphate (S1P) and 
pro-angiogenic growth factors (GF) synergize to induce rapid and robust endothelial 
sprouting in 3D collagen matrices. 
In a proteomic screen designed to identify molecules relevant to angiogenesis, 
we found up-regulated levels of receptor for activated C kinase 1 (RACK1) and the 
intermediate filament protein, vimentin. RACK1 depletion reduced EC invasion. 
Silencing of vimentin or RACK1 decreased cell adhesion and attenuated with focal 
adhesion kinase (FAK) activation, which is indispensable for successful angiogenesis. 
Moreover, pro-angiogenic GFs enhanced RACK1 and vimentin association. RACK1, 
vimentin, and FAK, formed an intermolecular complex during S1P- and GF- induced 
invasion. Also, depletion of RACK1 decreased vimentin and FAK association, 
suggesting a role for RACK1 in stabilizing vimentin-FAK interactions during sprouting.  
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In an independent study, we identified focal adhesion (FA) scaffold protein, 
hydrogen peroxide inducible clone 5 (Hic-5), as a critical regulator of angiogenesis. Hic-
5 depletion interfered with endothelial invasion and lumen formation. S1P induced rapid 
Hic-5 translocation to FAs and Hic-5 silencing attenuated FAK expression and 
activation. S1P induced a novel interaction between Hic-5 and membrane type 1 matrix-
metalloproteinase (MT1-MMP). In vitro binding experiments revealed that LIM2 
domain of Hic-5 was required for MT1-MMP binding. Moreover, Hic-5 and MT1-MMP 
levels were up-regulated in detergent resistant membrane fractions of invading ECs, 
indicative of their crosstalk. Hic-5 silencing interfered with S1P- induced MT1-MMP 
membrane translocation, a critical event for successful angiogenesis. Since MT1-MMP 
and FAK interaction has been reported to be essential for matrix degradation at FA sites, 
we further tested if Hic-5 mediated this interaction. Our results indicated that presence of 
Hic-5 significantly enhanced FAK and MT1-MMP complex formation.  In conclusion, 
we report that scaffold proteins RACK1 and Hic-5 regulate successful endothelial 
sprouting responses in 3D matrices. 
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NOMENCLATURE 
 
bFGF Basic fibroblast growth factor 
EC Endothelial cell 
ECM Extracellular matrix 
EDG Endothelial differentiation gene 
FA Focal adhesion 
FAK Focal adhesion kinase  
Hic-5 Hydrogen peroxide inducible clone 5 
HUVEC Human umbilical vein endothelial cells 
LD Asp and Leu rich 
LIM Lin11, Isl-1 & Mec-3 
MT1-MMP Membrane type 1 matrix-metalloproteinase 
PTX Pertussis toxin 
RACK1 Receptor for activated C kinase 1  
S1P Sphingosine 1-phosphate 
VEGF Vascular endothelial growth factor 
VE-cadherin Vascular endothelial cadherin 
VIM Vimentin 
WD-repeat tryptophan-aspartate repeat  
3D Three dimensional 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW* 
Angiogenesis is defined as the formation of new blood vessels that arise from 
pre-existing vasculature.  Angiogenesis is also referred to as neovascularization and 
plays a key role in several physiological processes such as embryonic growth and 
development, pregnancy, ovulation, and wound healing, [1, 2]. Loss of angiogenic 
regulation results in uncontrolled angiogenesis, which is a common denominator in 
several human disorders, including but not limited to, cancer [3, 4], rheumatoid arthritis 
[4, 5], coronary artery disease [6, 7], Alzheimer’s disease [8], stroke [9], diabetic [10, 
11], atherosclerosis [12], age-related macular degeneration [13, 14], hypertension [15], 
chronic wounds [16] and ulcers [17]. Thus, understanding molecular signaling pathways 
that regulate angiogenesis becomes instrumental.  
During angiogenesis, normally quiescent endothelial cells (ECs) lining blood 
vessels, are activated in response to external pro-angiogenic cues and undergo rapid 
morphogenic changes such as proliferation, basement membrane degradation, sprout 
initiation, migration, invasion, and lumen formation to extend new sprouts into the 
surrounding three-dimensional (3D) matrix [18-21].  
 
*Part of this section is reprinted with permission from “Vimentin as an integral regulator of cell adhesion 
and endothelial sprouting” by Dave JM and Bayless KJ, 2014. Microcirculation., 21(4):333-44, Copyright 
2014 by  John Wiley & Sons Inc.  
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Several pro-angiogenic factors have been reported that stimulate robust 
endothelial sprouting responses in vitro and in vivo (Table 1).  Vascular endothelial 
growth factor (VEGF) has been identified as a key driver of physiological angiogenesis 
during embryogenesis, skeletal growth, and reproduction [22, 23]. Other growth factors 
such as basic fibroblast growth factor (bFGF) [24], platelet derived growth factor BB 
(PDGF-BB) [25], and stromal derived factor 1α (SDF-1α) [26] have also been reported 
to promote tube formation in ECs. Sphingosine 1- phosphate (S1P), a blood-borne lipid 
mediator which is known to play crucial role in barrier enhancement, vascular 
maturation and angiogenesis, stimulates endothelial sprouting in vitro [27, 28]. Wall 
shear stress and fluid forces have also emerged as regulators of endothelial 
morphogenesis and vessel remodeling [29, 30]. ECs lining blood vessels are exposed to 
mechanical forces tangential to the cell surface due to blood flow [30-32].  Importantly, 
ECs must integrate multiple biochemical and mechanical signals, which activate various 
intracellular signaling pathways that are well-described to regulate angiogenesis. A wide 
range of intracellular molecules have been identified to respond to exogenous pro-
angiogenic stimuli and regulate endothelial sprouting responses. The extensive list 
includes actin binding proteins, microtubules, intermediate filaments, junctional 
proteins, integrins, kinases, ion channel proteins, small GTPases, proteases, surface 
receptors, and scaffold proteins (Table 1). 
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Table 1.  Molecules known to stimulate angiogenesis 
 
Category Proteins In vitro studies In vivo studies 
Exogeneous 
pro-angiogenic 
stimuli 
Vascular 
endothelial 
growth factor 
(VEGF) 
Senger et al., 1983 [33] 
Pepper et al., 1992 [34] 
Nicosia et al., 1994 [35] 
Mandriota and Pepper; 1997 
[36] 
 
Leung et al., 1989 [37] 
Plouet et al., 1989 [38] 
Connolly et al., 1989 [39] 
Phillips et al., 1994 [40] 
Tolentino et al., 1996 [41] 
Carmeliet et al., 1996 [42] 
Ferrara et al., 1996 [43] 
Basic fibroblast 
growth factor 
(bFGF) 
Shing et al., 1984 [44] 
Montesano et al., 1986 [45] 
Pepper et al., 1992 [34] 
Presta et al., 2005 [46] 
 
Shing et al., 1985 [47] 
Presta et al., 1986 [48] 
Gualandris et al., [49] 
 
Platelet derived 
growth factor BB 
(PDGF-BB) 
Battegay et al., 1994 [25] 
Nicosia et al., 1994 [35] 
Brown et al., 1995 [50] 
Xue et al., 2011 [51] 
Stromal derived 
factor 1α (SDF-
1α) 
Saunders et al., 2006 [26] 
Mirshahi et al., 2000 [52] 
Ara et al., 2005 [53] 
Sphingosine 1- 
phosphate (S1P) 
Lee et al., 1999 [54] 
Wang et al., 1999 [55] 
Garcia et al., 2001 [28] 
Bayless and Davis; 2003 [27] 
Oyama et al., 2008 [56] 
Nitric oxide (NO) Ziche et al., 1994 [57] 
Ziche et al., 1994 [57] 
Lee et al., 1999 [58] 
Fukumura et al., 2001 [59] 
Amano et al., 2003 [60] 
Wall shear stress 
(WSS) 
Kang et al., 2008 [61] 
Kang et al., 2011 [30] 
Jung et al., 2012 [62] 
Ichioka et al., 1997 [63] 
Zhou et al., 1998 [64] 
Lucitti et al., 2007 [65] 
Jung et al., 2012 [62] 
Interstitial flow Song et al., 2011 [66]  
Mechano-
transduction 
Reviewed in: 
Egginton, 2011 [67] 
Kaunas et al., 2011 [29] 
Roman et al., 2012 [68] 
Reviewed in: 
Egginton, 2011 [67] 
Kaunas et al., 2011 [29] 
Roman et al., 2012 [68] 
Intermediate 
filaments 
Vimentin Kwak et al., 2012 [69] 
Eckes et al., 2000 [70] 
Lundkvist et al., 2004 [71] 
Neiminen et al., 2006 [72] 
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Table 1.  Continued 
 
Category Proteins In vitro studies In vivo studies 
MTs 
(Microtubules) 
MT tip complex 
proteins 
Kim et al., 2013 [73]  
MT 
depolymerizing 
factors 
Reviewed in Bayless and 
Johnson; 2011 [74] 
Reviewed in Bayless and 
Johnson; 2011 [74] 
Actin binding 
proteins 
Filamin A  Feng et al., 2006 [75] 
Proteases 
Calpains 
Su et al., 2006 [76] 
Kang et al., 2011 [30] 
Kwak et al., 2012 [69] 
Su et al., 2006 [76] 
Hoang et al., 2010 [77] 
Hoang et al., 2011 [78] 
MT1-MMP 
Hiraoka et al., 1998 [79] 
Hotary et al., 2000 [80] 
Bayless and Davis, 2003 [27] 
Chun et al., 2004 [81] 
Saunders et al., 2006 [26] 
Kang et al., 2008 [61] 
Holmbeck et al., 1999 [82] 
Zhou et al., 2000 [83] 
Chun et al., 2004 [81] 
Small GTPases 
Rac1 
Bayless and Davis; 2002 [84] 
Koh et al., 2008[85] 
Kamei et al., 2006  [86] 
Hoang et al., 2011 [87] 
Cdc42 
Bayless and Davis; 2002 [84] 
Koh et al., 2008 [85] 
Sacharidou et al., 2010 [88] 
Kamei et al., 2006  [86] 
Hoang et al., 2011 [89] 
Rap1 
Yan et al., 2008 [90] 
Carmona et al., 2009 [91] 
 
Rho 
Hoang et al., 2004 [92] 
Liu and Senger; 2004 [93] 
Hoang et al., 2004 [92] 
Garnaas et al., 2008 [94] 
Integrins 
α2β1 
Davis and Camarillo, 1996 
[20] 
Senger et al., 1997 [95] 
Senger et al., 2002 [96] 
San Antonio et al., 2009 [97] 
α1β1  
Senger et al., 1997 [95] 
Senger et al., 2002 [96] 
α4β1  Garmy-Susini et al., 2005 [98] 
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Table 1.  Continued 
Category Proteins In vitro studies In vivo studies 
Integrins 
α5β1 Bayless et al., 2000 [99] Kim et al., 2000 [100] 
αvβ3 Bayless et al., 2000 [99] 
Brooks et al., 1994 [101] 
Drake et al., 1995 [102] 
Friedlander et al., 1995 [103] 
Hammes et al., 1996 [104] 
Bader et al., 1998 [105] 
αvβ5  Friedlander et al., 1995 [103] 
Kinases 
Focal adhesion 
kinase (FAK) 
Cabrita et al., 2011 [106] 
Dave et al., 2013 [107] 
Shen et al., 2005 [108] 
Braren et al., 2006 [109] 
Tavora et al., 2010 [110] 
PKCε Koh et al., 2008  [85]  
GSK-3β  Hoang et al., [89] 
Pak 
Koh et al., 2008  [85] 
Koh et al., 2009 [111] 
Kiosses et al., 2002 [112] 
Src 
Koh et al., 2009  [111] 
Liu and Senger; 2004  [93] 
Reviewed in Rak et al., 1995 
[113] 
Raf kinase Koh et al., 2009  [111] 
Reviewed in Rak et al., 1995 
[113] 
Hamden et al., 2005 [114] 
Akt 
Dimmeler et al., 1998 [31] 
Igarashi et al., 2001[115] 
Morales-Ruiz et al., 2001 
[116] 
Kang et al., 2008 [61] 
Dimmeler et al., 1998 [31] 
Ackah et al., 2005 [117] 
 
Junctions 
VE-cadherin Yang et al., 1999 [118] 
Carmeliet et al., 1999 [119] 
Gory-Faure et al., 1999 [120] 
Montero-balaguer et al., 2009 
[121] 
Wang et al., 2010 [122] 
PECAM-1 
DeLisser et al., 1997 [123] 
Yang et al., 1999 [118] 
Cao et al., 2002 [124] 
Cao et al., 2009 [125] 
Duncan et al., 1999 [126] 
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Table 1.  Continued 
Category Proteins In vitro studies In vivo studies 
Ion channel 
proteins 
Clic4 
Ulmasov et al., 2009 [127] 
Tung et al., 2009 [128] 
Ulmasov et al., 2009 [127] 
Clic1 Tung et al., 2010 [129]  
Scaffold 
proteins 
Receptor for 
Activated C 
Kinase 1 
(RACK1) 
Dave et al., 2013 [107] Berns et al., 2000 [130] 
Annexin 2 
(ANXA2) 
Su et al., 2010 [131] Heyraud et al., 2008 [132] 
Moesin  Wang et al., 2010 [122] 
Hypoxia 
HIF pathway 
 
Tang et al., 2004 [133] 
Skuli et al., 2012 [134] 
Skuli et al., 2012 [134] 
Cell surface 
receptor 
Par3 
Koh et al., 2008 [85] 
Dejana and Vestweber? 
Nakayama et al., 2013 
[135]Dejana and Vestweber? 
Robo1 Sheldon et al., 2009 [136]  
Robo4 Sheldon et al., 2009 [136] 
Huminiecki et al., 2002 [137] 
Park et al., 2003 [138] 
Suchting et al., 2005 [139] 
Koch et al., 2011 [140] 
Notch 
Taylor et al., 2002 [141] 
Sainson et al., 2005 [142] 
Seikmann et al., 2007 [143] 
Suchting et al., 2007 [144] 
Hellstrom et al., 2007 [145] 
Dufraine et al., 2008 [146] 
Delta like 4 
(Dll4) 
Su et al., 2009 [147] 
Lobov et al., 2007 [148] 
Al Haj Zen et al., 2010 [149] 
UNC5B/ Netrin-
1 
Larrivee et al., 2007 [150] 
Lu et al., 2004[151] 
Park et al., 2004 [152] 
Navankasattusas et al., 2008 
[153] 
Koch et al., 2011 [140] 
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Several in vivo and in vitro models have been employed to study this dynamic 
process, since standard two dimensional (2D) cell culture techniques fail to replicate 
individual steps of angiogenesis such as sprout initiation, invasion, and lumen formation. 
Tumor angiogenic studies gained momentum when Judah Folkman first proposed that 
tumor growth required angiogenesis [33]. Chorioallantoic membrane (CAM) assays are 
another method to test angiogenic cytokines that can be placed directly onto a 7-9 day 
old embryo to visualize vascularization [34]. Another elegant model to study 
angiogenesis in vivo is the corneal assay which monitors penetration of new blood 
vessels into the normally avascular cornea in response to tumor fragments or angiogenic 
factors [35].  For studies of physiological angiogenesis, development and pregnancy 
provide ideal model systems and have been used extensively [36]. More recently, the 
zebrafish has emerged as a viable whole animal model to study angiogenesis, which has 
an advantage of allowing detailed live imaging of vessel formation in a vertebrate 
embryo that can be genetically manipulated with relative ease [37, 38].   
The ability to isolate and culture ECs has facilitated the development of several 
in vitro techniques to study angiogenesis.  Early independent studies by Sage and 
Montesano cultured ECs with growth factors and phorbol esters in 3D collagen or fibrin 
matrices [39, 40]. Nicosia and colleagues demonstrated that rat aortic rings reproducibly 
generated microvessel outgrowths in fibrin or collagen matrices, and provide a sensitive 
ex vivo assay to screen pro- and anti-angiogenic substances [41]. A variety of in vitro 
assays have subsequently been developed that mimic different stages of angiogenesis. 
  
8 
 
 
These include (i) bead assays, in which ECs coated on  microcarrier beads are embedded 
in 3D matrices [42]; (ii) vasculogenesis assay; where ECs suspended in collagen or 
fibrin matrices undergo tubulogenesis [43]; (iii) microvessel fragment assay which 
involves embedding microvascular fragments isolated from adipose tissue into 3D 
matrices [44]; (iv) EC monolayer invasion assay, in which ECs seeded as a monolayer 
on collagen or fibrin matrices undergo sprouting perpendicular to the monolayer [27, 45, 
46]; and (v) a sandwich method, where an EC monolayer is placed between two collagen 
matrices to initiate tube formation [46].   
In this study, we have used a 3D in vitro angiogenic model where the synergistic 
effects of sphingosine- 1- phosphate (S1P) and angiogenic growth factors (GFs), 
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), 
induce robust and rapid endothelial sprouting responses in 3D collagen matrices (Figure 
1) [45]. This model mimics wound environment wherein, platelets deposit S1P and 
VEGF at the wound site, whereas bFGF is secreted by fibroblasts and other cells to 
induce angiogenesis [47-51].  
  
9 
 
 
 
Figure 1: 3D in vitro angiogenic model 
 
 
 
 
Sphingosine- 1-phosphate (S1P) is a blood borne lipid mediator that has been 
widely reported to induce angiogenesis [52-54]. S1P is released from ceramide by 
enzyme ceramidase. Sphingosine kinase phosphorylates sphingosine to produce S1P 
[55]. S1P is known to function primarily as a regulator of vascular and immune systems. 
S1P stimulates growth, suppresses apoptosis, increases thermo tolerance and regulates 
motility, cytoskeletal rearrangement and cellular Ca2+ levels [55]. S1P acts through one 
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or more of its five known G protein- coupled receptors (GPCRs), S1P1–S1P5 [55, 56], 
which were originally named Endothelial Differentiation Gene (EDG receptors). ECs 
express receptors, EDG-1 (S1P1) and EDG-3 (S1P3) [56]. Both S1P1 and S1P3 are Gi 
coupled receptors, and can be inactivated by pertussis toxin (PTX). PTX blocks S1P 
receptor activity by catalyzing ADP-ribosylation of α subunits of heteromeric G proteins 
(G0, Gi, and Gt) thus preventing G proteins from interacting with their receptors and 
interfering with intracellular communication [57]. Thus, PTX can be used as an effective 
tool to dissect downstream S1P signaling.  
S1P1 null mice exhibit vascular defects, and impaired mural cell (smooth muscle 
cells and pericytes) association with developing vasculature [58]. In ECs, S1P plays a 
significant role in adherens junction assembly, chemotaxis, cell spreading, membrane 
ruffling, morphogenesis into capillary like networks and cord formation on matrigel [59-
62]. S1P- mediated endothelial functions have been shown to be dependent on small 
GTPases Rho and Rac [63, 64]. S1P is also known to play critical role in FA (focal 
adhesion) assembly. S1P treatment directs translocation of several focal proteins to and 
FA sites, thus regulating FA growth and turnover [65]. In addition, S1P was shown to 
induce membrane translocation of MT1-MMP, a critical step towards successful 
angiogenesis [54, 66].  Previous studies from our laboratory have also shown that S1P 
induced membrane translocation of annexin 2, a scaffold protein required to maintain 
VE-cadherin based junctional integrity in sprouting ECs [67]. Moreover, results from 
our laboratory have also indicated that S1P in combination with wall shear stress (WSS) 
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is sufficient for endothelial sprouting [30, 68]. Thus, S1P acts through several 
downstream effector molecules in ECs to induce EC activation and sprouting.  
The VEGF family consists of seven members including VEGF-A through -E, 
placental growth factor (PlGF) and T.f. svVEGF (derived from snake venom of 
Trimeresurus flavoviridis) [69]. VEGF-A or VEGF was first isolated in 1983 by Senger 
et al., which had strong vascular permeability activity and was named vascular 
permeability factor (VPF) [70]. Extensive studies have revealed that VEGF-A is not only 
important in vasculogenesis and growth of new blood vessel formation from endothelial 
progenitor cells (EPCs), but also for angiogenesis, growth of new blood vessels from 
pre-existing ones and tumor angiogenesis [71]. VEGF ligands induce intracellular 
changes by binding to specific VEGF receptors (VEGFRs) [72]. VEGFR is a subfamily 
of the large protein tyrosine kinase receptors (PTKRs) family and comprises of three 
members VEGFR-1, -2 and -3. PTKR family comprises of 20 subfamilies which include 
FGFR, PDGFR, EGFR, and insulin receptors among others. VEGF ligands show 
specificity in binding to VEGFRs [72]. VEGF-A binds only VEGFR1 and R2 whereas 
VEGF-C and –D, which are involved in regulation of lymphangiogenesis, bind VEGFR2 
and R3 [73, 74].  
VEGF-A is a disulfide linked homodimer of 40 kDa. In adults, VEGF-A is 
stimulated during wound healing and female menstrual cycle. Pathologically, increased 
VEGF-A levels have been reported in various cancers and autoimmune diseases such as 
rheumatoid arthritis, multiple sclerosis diabetic retinopathy, age-related macular 
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degeneration and arthrosclerosis [75-78]. Many studies have shown increased levels of 
VEGF mRNA in tumor lines [79-81]. Also, many tumors secrete VEGF-A in vitro [82, 
83]. VEGF-A promotes differentiation of EPCs in the early embryo, and stimulates 
vascular EC growth, survival, tube formation, and migration [84]. VEGF-A knockout in 
mice is embryonic lethal even in heterozygotes, strongly suggesting a critical role for 
VEGF-A during development. Lethality arises from multiple defects in angiogenesis 
such as disconnection of heart with aorta and poor development of dorsal aorta [85]. 
VEGF-A is alternatively spliced to generate nine isoforms of from 121 to 109 aa in 
length. VEGF-A is the most common form (165 aa) and, owing to its mild affinity for 
heparin, it exists as bound as well as soluble forms [86]. The signaling mechanism of 
VEGF/VEGFR is similar to that of many PTKRs [87]. The major pathways activated by 
VEGF are the phospholipase Cγ (PLCγ) pathway, phosphoinositol 3-kinase (PI3K) and 
Ras/MEK/MAPK pathway [88, 89]. 
Basic fibroblast growth factor (bFGF) or FGF2 is a heparin binding growth 
factor, which was first discovered by Judah Folkman in 1984 [90]. This 18.8 kDa protein 
stimulated potent angiogenic activity in vitro and in vivo [91]. In ECs, bFGF stimulated 
cell proliferation, capillary morphogenesis, DNA synthesis. motility and protease up-
regulation (MMPs and uPA) [92-94]. bFGF also regulates expression of cadherins and 
integrins to direct vessel maturation and cell adhesion to ECM [92]. bFGF has been 
shown to promote robust neovascularization in several models like CAM assay, cornea 
assay and matrigel plug assay [92]. Four isoforms are known to be co-expressed by fgf2 
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gene in humans, out of which the 24 and 18 kDa isoforms induce maximal 
neovascularization [95, 96]. Interestingly, fgf2 knockout mice do not display any defects 
in neovascularization following hypoxia [97] or injury [98], suggesting redundancy of 
FGF family members [99, 100]. 
bFGF exerts most of its effects by interacting with its cognate tyrosine kinase 
receptors expressed on the EC surface. Four bFGF receptors have been identified 
(FGFR1-FGFR4), which display structural variability and different binding affinity for 
bFGF isoforms [101, 102]. FGFR1 [103] and FGFR2 [104] are expressed of in ECs. 
Interaction of bFGF with FGFR results in receptor dimerization and autophosphorylation 
of specific Tyr residues and activation [105-108]. Some of the key molecules known to 
be activated by bFGF are FAK [109], Src [109], PLCγ [110], PI3K [111, 112] and 
Ras/MEK/MAPK pathway [109, 113-115]. 
In this study, we have identified two scaffold proteins that are essential for 
angiogenesis by using the S1P, VEGF and bFGF driven 3D in vitro angiogenic model 
(Figure 1). Our results indicated that scaffold protein Receptor for Receptor for 
Activated C Kinase 1 (RACK1) was upregulated during S1P- and GF- induced invasion 
and was required for successful sprouting responses. Moreover, GFs induced complex 
formation between RACK1 and intermediate filament protein vimentin, to regulate cell 
attachment, migration and focal adhesion kinase (FAK) activation and expression. In 
another study, we identify FA scaffold protein, Hic-5, to be required for successful 
endothelial sprouting and lumen formation. Our data indicated that Hic-5 was required 
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for membrane type 1 matrix-metalloproteinase (MT1-MMP) regulation and FAK 
expression and activation in ECs. In conclusion, these two studies show for the first time 
a direct requirement for RACK1 and Hic-5 in successful endothelial sprouting in 3D 
matrices. These enclosed studies also explore how RACK1 and Hic-5 regulate 
downstream effector proteins that are known to be important for angiogenesis. 
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CHAPTER II 
PROTEOMIC PROFILING OF ENDOTHELIAL INVASION REVEALED 
RECEPTOR FOR ACTIVATED C KINASE 1 (RACK1) COMPLEXED WITH 
VIMENTIN TO REGULATE FOCAL ADHESION KINASE (FAK)* 
 
INTRODUCTION 
 In this study, we report that Receptor for Activated C Kinase 1 (RACK1) was 
differentially expressed in two independent proteomic screens designed to dissect the 
downstream targets of S1P-induced endothelial invasion. RACK1 is a member of the 
tryptophan-aspartate repeat (WD-repeat) family of proteins and was originally named for 
associating with Protein kinase C beta type III. However, it is now well known that 
RACK1 interacts with several proteins and plays roles in shuttling and anchoring them 
to specific subcellular locations and stabilizing their activity [116, 117]. RACK1 is 
critical for development [118-120], cell proliferation and migration [121-124], and 
circadian rhythms [125].  
 
*Part of this research was originally published in the Journal of Biological Chemistry. Dave JM, 
Kang H, Abbey CA, Maxwell SA, Bayless KJ. “Proteomic profiling of endothelial invasion revealed 
receptor for activated C kinase 1 (RACK1) complexed with vimentin to regulate focal adhesion 
kinase (FAK).” J Biol Chem. 2013; 288(42): 30720-33. © The American Society for Biochemistry 
and Molecular Biology. 
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RACK1 mediates effects on cell migration mostly through regulation of FA 
assembly by promoting FAK activation downstream of integrin clustering and adhesion 
[122, 123, 126, 127]. Studies in RACK1 null mice have not been reported, however, 
Berns et al. demonstrated that RACK1 was up-regulated during cord formation in bovine 
aortic ECs in vitro and in angiogenically active tissues such as corpora lutea, ovarian 
follicles, and human carcinomas in vivo [128]. Although these reports suggest a relevant 
role for RACK1 during angiogenesis, the molecular events directed by RACK1 remain 
unclear. 
 The major intermediate filament protein, vimentin, was also identified in a 
proteomic screen as a downstream target of S1P-induced EC invasion. Our laboratory 
has shown vimentin depletion in ECs resulted in poor invasion responses [66]. Recent 
studies in mouse fibroblasts suggest that vimentin may stabilize FA assembly [129] and 
regulate FA contact size in response to shear stress [130]. Focal adhesions (FAs) are 
dynamic macromolecular assemblies that link cells to the extracellular matrix (ECM) 
[131-135]. FAK is a major tyrosine kinase protein concentrated at FAs. ECM 
engagement and integrin assembly promote FAK phosphorylation which further recruits 
and phosphorylates other proteins at FAs, to promote cytoskeletal rearrangement and 
cell migration [136-138]. FAK has been extensively studied in cell migration, 
angiogenesis, and cardiac morphogenesis [139-142].  
 In this study, we show for the first time a trimolecular complex between RACK1, 
vimentin, and FAK in three-dimensional invading cultures. Knockdown of RACK1 
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resulted in poor invasion responses and attenuated FAK activation, whereas vimentin 
depletion resulted in decreased FAK expression in ECs. Furthermore, RACK1 was 
needed to stabilize the complex between vimentin and FAK.  
 
EXPERIMENTAL PROCEDURES 
 
Endothelial  Cell Culture and Invasion  
 Human umbilical vein endothelial cells (HUVECs; Lonza, Allendale, NJ), 
passages 3-6, were cultured as previously described [45]. Three dimensional (3D) 
invasion experiments were established using 40 ng/mL VEGF and bFGF growth factors 
alone (GF) or S1P and GFs (S1P+GF) or S1P and GF plus 0.1 µg/mL pertussis toxin 
(S1P+GF+PTX). Collagen matrices (2.5 mg/mL) containing 0 or 1 µM S1P (Avanti 
Polar Lipids, Alabaster, AL) were prepared as described previously, and invasion 
responses where indicated, were quantified for invasion density as previously described 
in detail [45].  
Proteomic Screen 1: Differential In-Gel Electrophoresis (DIGE)  
 Collagen gels from 12.5 h invading cultures (S1P+GF or S1P+GF+PTX) were 
collected and incubated in M199 containing 10 µg/mL collagenase (Sigma), and HALT 
Phosphatase Inhibitor Cocktail (Thermo Scientific, Ashville, NC) at 37°C for 10 
minutes. For each condition, 240 gels were prepared. Cells were pelleted at 500xg for 5 
minutes and washed once in ice-cold PBS. Cell pellets were flash-frozen in liquid 
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nitrogen and stored at -80°C. Frozen cell pellets were lysed by thawing and pipetting on 
ice in 1 mL of lysis solution I (0.3% SDS; 200 mM dithiothreitol; 50 mM Tris, pH 7.5; 
broad range protease inhibitors (GE Healthcare, Waukesha, WI); HALT Phosphatase 
Inhibitor Cocktail (Thermo Scientific). Proteins were further solubilized by heating at 
100°C for 10 minutes followed by incubating on ice for 5 minutes. Lysates were 
sonicated with a 15 seconds burst (amplitude setting 60) on ice using a Sonics Vibracell 
sonicator to further fragment DNA and cytoskeletal structures. Nucleic acids were 
digested by adding DNase/RNase mix (GE Healthcare) and rotating the lysates at 4°C 
for 45 minutes. Lysates were delipidated in chloroform-methanol by adding 4 mL of 
methanol and vortexing for 30 seconds, followed by adding 1 mL of chloroform and 
vortexing for 30 seconds, and finally by adding 3 mL of Millipore-purified water and 
vortexing for 60 seconds. Samples were rotated at room temperature for 15 minutes, 
transferred to corex glass tubes, and centrifuged at 5500xg in a Sorvall JA20 rotor for 20 
minutes at room temperature. The interphase contained the proteins, which was 
transferred to a microfuge tube and mixed with 0.5 mL of methanol. After spinning for 
10 minutes in a microfuge, the pellets were resuspended in 0.6 mL of water and proteins 
re-precipitated by adding a 0.8 volume of ice-cold acetone and incubating on ice for 15 
minutes. Proteins were pelleted out of the acetone solution by spinning in a microfuge 
for 15 minutes and re-solubilized in 100 mL of a 2D gel proteomic solubilization buffer 
(9.9 M urea; 4% CHAPS; 14% thiourea; 4.8% SDS; 10 mM Tris, pH 7.5; 40 mM DTT).  
Proteins were allowed to solubilize for 1 h by rotating at room temperature and then 
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desalted through microspin desalting columns (Pierce Protein Biology, Rockford, IL) 
into desalting solution (9.9 M urea; 4% CHAPS). Protein concentrations were 
determined by the BCA protein assay after pre-treating and re-precipitating an aliquot of 
each sample with BCA compatibility reagent and Compat-Able protein assay 
preparation set (Pierce cat. #23250 and #23215, respectively) to eliminate interference 
from BCA protein reagent with thiourea. After determining protein concentration, the 
samples were adjusted to 50 mg protein/10 mL desalt buffer I and subjected to a second 
spin through a desalting microspin column into DIGE labeling buffer (9.9 M urea; 4% 
CHAPS; 30 mM Tris-HCl, pH 8). 
 Protein samples were prepared for differential gel electrophoresis (DIGE), which 
is based on pre-labeling of different protein fractions with cyanine-based fluors (CyDye 
DIGE Fluor minimal dyes) and their subsequent co-electrophoresis in a single 2D gel. 
The DIGE technology has the advantage of allowing elimination of inconsistencies 
based on gel to gel variations and the exact quantification of proteins spots separated by 
gel electrophoresis. Proteins in DIGE labeling buffer (150 mg in 30 mL volume) were 
covalently-attached to CyDyes (Cy5, Cy3, Cy2) using the manufacturer’s protocol (GE 
Healthcare). A 500 mg aliquot (75 mL volume) of a pooled total protein preparation 
consisting of unlabeled CHOP-sensitive and -resistant cells was then added to each 
CyDye-labeled protein sample.  This allowed each gel to be a preparative gel for picking 
spots for mass spectrometry. The CyDye-labeled preparative protein samples were then 
passed through a desalting microspin column equilibrated with desalting solution to 
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remove free CyDye reagents and buffer. Desalted CyDye-labeled protein lysates (~100 
mL) were mixed with 400 mL of Destreak Rehydration sample buffer (GE Healthcare 
Life Sciences) containing 0.077 mg of DTT. Protein samples were solubilized by 
rotating for 1 h at room temperature. After adding another 0.077 mg DTT and 
ampholytes (100X Bio-Lyte pI 3-10 ampholytes, Bio-Rad, Hercules, CA), samples were 
rotated for 30 minutes at room temperature and then allowed to rehydrate pH 3-10 
Immobiline dry-strip gel strips (GE Healthcare Life Sciences) for 18 h.  Rehydrated 
Immobiline dry strips were subjected to step-wise isoelectric focusing at 150 V for 6 h, 
500 V for 1 h, 1000 V for 1 h, and 8000 V for 6 h in an Ettan IPGphorII unit.  Proteins 
were then separated in the second dimension on large format (27 x 21 cm) 8-16% 
gradient SDS polyacrylamide gels at 5 W/gel for 9.5 h. CyDye-labeled proteins in the 
2D gels were imaged with a Typhoon 9200 laser scanner. A gel selected for spot-picking 
was counter-stained with Sypro Red for 6 h in 7.5% acetic acid, destained for 1 h in 
7.5% acetic acid, and re-imaged in a Typhoon 9200 laser scanner. Image analysis was 
performed using the Biological Variation Analysis (BVA) modules of the DeCyder 
software version 5.0 (GE Healthcare), which first normalizes each sample to its 
respective in-gel Cy2 internal standard, and then matches all controls and samples 
between different gels. Comparing each group in the BVA module generated average 
expression ratios and Student’s t-tests of individual protein spots. 
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Proteomic Screen 2: Two-Dimensional Gel Electrophoresis 
Two-dimensional gel electrophoresis was performed as previously described 
[143]. 
In Gel Digestion 
 Spot-picking and in-gel digestion were carried out robotically at the Protein 
Analysis Laboratory, Texas A&M University, on selected Sypro Red-stained preparative 
gels using the Ettan Spot Picker and the Ettan Digester (GE Healthcare). For in-gel 
digestion, protein spots of interest (1.4 expression ratio or greater) were excised, and the 
gel plugs washed twice for 15 minutes in 50% Acetonitrile (ACN)/50mM Ammonium 
Bicarbonate (ABC).  The plugs were washed once more with 100% ACN for 15 minutes 
and then dried by centrifugal lyophilization for 30 minutes.  In-gel digestion was 
conducted by adding 20 mL of trypsin (20 ng/mL) and incubating for 15 minutes.  After 
adding 100 µL of 25 mM ABC, the gel plugs were incubated at 37°C overnight.  The 
supernatants were removed and saved.  A solution of 80% ACN/0.1% trifluoracetic acid 
was added to the gel plug for 30 minutes.  The supernatant was then removed and pooled 
with the first supernatant.  The peptide volume was reduced down to 10 µL by 
centrifugal lyophilization and then subjected to LCMS. 
Protein Identification 
 LCMS was carried out on a ThermoFinnagan (Thermo Electron, Asheville, NC) 
LCQDecaXP (ESI-TRAP model). Samples were run using an in-house packed C18 
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reverse phase nanospray needle. Mass spectra were used to interrogate human sequences 
in the NCBInr database (5/2009; 478,579 entries human database). The automatic data 
analysis and database searching were fulfilled by the TurboSEQUEST software in the 
Bioworks Browser (version 3.3.1 SP1). Searches with TurboSEQUEST were performed 
to allow for a maximum of two missed trypsin cleavages. Additional TurboSEQUEST 
search parameters were as follows: mass typesetting was monoisotopic precursor and 
fragments; threshold tolerance was 50,000; peptide tolerance, precursor ion tolerance, 
and fragment ion tolerance were 2.5000, 1.4000 and 0.0001 AMU, respectively.   Ions 
and ion series calculated were B and Y ions. Searches were also conducted using the 
MASCOT search engine (www.matrixscience.com). The database searched by 
MASCOT was NCBInr 20070216 (4626804 sequences; 1596079197 residues) and the 
taxonomy was Homo sapiens (human) (191437 sequences). MASCOT search 
parameters were as follows: fixed modifications, carboxymethyl; variable modifications, 
oxidation (M); mass values, monoisotopic; protein mass, unrestricted; peptide mass 
tolerance, ± 1.8 Da; fragment mass tolerance: ± 0.8 Da. The search identification had a 
statistically significant p<0.05 (based on mass/mass spectra). Redundancy of proteins 
that appeared in the database under different names and accession numbers was 
eliminated. If more than one protein was identified in one spot, the single protein 
member with the highest protein score (top rank) was singled out from the multiprotein 
family.  
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Immunoblotting 
 Total cell lysates were prepared by solubilizing collagen matrices in boiling 1.5X  
Laemmli sample buffer at 95°C for 10 min. Protein samples were resolved by using 8.5-
14% SDS-PAGE, transferred onto Immobilon PVDF membranes (Millipore), blocked 
with 5% nonfat dry milk or 5% BSA, washed,  and probed with primary antibodies 
overnight at 4°C. Membranes were incubated with HRP conjugated secondary 
antibodies, washed, and developed using Immobilon Western Chemiluminescent HRP 
Substrate (Millipore) using HyBlot CL autoradiography film (Denville Scientific, South 
Plainfield, NJ). The antibodies used are: vimentin (sc-5565 and sc-6260, Santa Cruz 
Biotechnology, Temecula, CA), ANXA2 (AF3928, BD Transduction Laboratories, San 
Jose, CA), RACK1 (sc-17754, Santa Cruz Biotechnology) (ab119442, Abcam, 
Cambridge, MA), α-tubulin (T6199, Sigma-Aldrich), FAK (3285, Cell Signaling, 
Danvers, MA) (05-537, Millipore), pFAK (Tyr397, 8556, Cell Signaling), β2M (M8523, 
Sigma), α-actinin (A-2543, Sigma), GAPDH (ab8245, Abcam), VE-cadherin (sc-52751, 
Santa Cruz Biotechnology), filamin A (MCA464ST, BioRad) and HRP conjugated 
secondary antibodies (Dako, Carpinteria, CA). 
Generation of Stable Cell Lines Using shRNA 
 Lentiviral vectors specific for RACK1 (#SHCLNG-NM006098), vimentin 
(#SHCLNG-NM011701), and β2M (#SHCLNG-NM004048) were purchased from 
Sigma-Aldrich. Lentiviral particles were generated by transfecting 1.25 μg of backbone 
shRNA lentiviral plasmid with 3.75 μg of VIRAPOWER packaging mix (Invitrogen) 
  
24 
 
 
into confluent 293FT cells (Invitrogen), using Lipofectamine 2000 (Invitrogen) in T25 
flasks. Viral supernatants were harvested at 60 h, centrifuged at 1500xg for 5 minutes 
and filtered through a 0.45 μm filter (Millipore, Rockland, MA). 25-30% confluent T25 
flasks of HUVECs were infected with 2 mL viral supernatant, 3 mL endothelial growth 
medium, and Polybrene (12 μg/mL; Sigma) for 4 h. HUVECs were allowed to grow for 
four days prior to use in experiments. 
mRNA Extraction and PCR Analysis 
HUVEC were treated with shRNAs to RACK1 (shRACK1 -1: TRCN 
0000273167; shRACK1 -2: TRCN 0000006472; and shRACK1 -3: TRCN 0000006471) 
and β2M (shβ2M -1: TRCN 0000057254; shβ2M -2:  TRCN 0000057255). RNA was 
extracted from HUVEC expressing shRNA as well as an untreated control, using an 
RNeasy MiniKit (Qiagen).  Eluted RNA was treated with RNase Free DNase (Qiagen) 
for 10 minutes at RT and inactivated at 65°C for 15 minutes. RNA quality was assessed 
with an agarose gel.  cDNA was generated by SuperScript III First-Strand Synthesis 
System  (Invitrogen) using 1 ug of RNA and Oligo(dT)20 as per manufacturer’s 
instructions.  Amplicons were run on 2% agarose gels in 1X TAE buffer at 120V for 20 
minutes with a 100 bp DNA ladder (Invitrogen) and stained with GelRed (Phenix 
Research Products, Candler, North Carolina). The primers used for this study were: 
ANXA2 (NM_001002858.2; 262 bp 5’-CAGAGGAT-GCTCTGTCATTG-3’ and 5’-
GGCTTGT- TCTGAATGCACTG-3’); PECAM1 (NM_000442.4; 172 bp 5’-
ATGATGCCCAGTTT- GAGGTC-3’ and 5’-ACGTCTTCAGTGGGGTTGTC-3’); 
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FAK (NM_153831.3; 217 bp 5’-CTGGCTACCCTG-GTTCACAT-3’ and 5’-
TGTTGCTGTCGGAT-TAGACG-3’); Vimentin (NM_003380.3; 177 bp 5’-
GGGACCTCTACGAGGAGGAG-3’ and  5’-AA- GATTGCAGGGTGTTTTCG-3’); 
RACK1 (NM_006098.4, 1000 bp 5’-CCACCATGA- CTGAGC-3’ and 5’-
GCGTGTGCCAATGGT-3’); VE-Cadherin (NM_001795.3, 182 bp 5’-C-
CAGGTATGAGATCGTGGTG-3’ and  5’-AA-ACAGAGAGCCCACAGAGG3’); 
β2M, (NM_ 004048.2, 158 bp 5’-TTTCATCCATCCGAC-ATTGAAG-3’ and 5’-
ACACGGCAGGCATAC-TCATC-3’); Filamin-A, (NM_001456.3, 243 bp 5’-
TCCAGCAGAAC-ACTTTCACG-3’ and 5’-CGATGGACACCAG-TTTGATG-3’) and 
GAPDH (NM_002046.4, 228 bp 5’-CGACCA-CTTTGTCAAGCTCA-3’ and  5’-
AGGGGTCTA-CATGGCAACTG-3’). 
shRACK1 Rescue Experiments 
HUVEC cDNA was used to amplify RACK1 insert using primers 5’-
GCAAGCTTGCCACCATGACTGAGCAC-3’ and 5’-GCGGTACCGCGTGTGCCAA- 
TGGTCAG-3’. RACK1 inserts were inserted into the pEGFP-C2 vector in the HindIII 
and Kpn1 sites. The resulting EGFP-RACK1 fusion construct was amplified using 5’-
AGGATATCCTAGCGTGTGCCAATGGT-3’and 5’- AGGTCGACGCCACCATGGT- 
GAGCAA-3’ primers. EGFP-RACK1 fusion was inserted into pENTR4 vector using 
SalI and EcoRV restriction sites. Inserts were validated by sequencing and recombined 
with pLenti6/V5-DEST (Invitrogen) in Stbl3 cells (Invitrogen). After confirming 
expression, EGFP-RACK1 in pLenti6/V5 was mutated at shRACK1-1 target site using 
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Quickchange Lightning site-directed mutagenesis kit (Stratagene, Invitrogen) according 
to manufacturer’s instructions. The rescue construct was designated as R3 because 
primers incorporated three base pair changes (5’- GGAAACTGACCCGGGACGAGAC- 
CAACTACGGAATTCCACAG-3’ and 5’-CCTTTGACTGGGCCCTGCTCTGGTTG- 
ATGCCTTAAGGTGTC-3’). In rescue experiments, HUVEC infected with shRNA 
directed against β2M (shβ2M) or RACK1 (shRACK1-1) were cultured for 48 h before 
infecting with lentiviruses R3 or GFP control rescue constructs. Lentiviruses (5 mL) 
were generated by transfecting 2 µg of backbone plasmids into confluent 293FT cells 
(Invitrogen) with 6 µg VIRAPOWER packaging vectors (Invitrogen) using 
Lipofectamine 2000 (Invitrogen). Viral particles were harvested at 60 h, centrifuged at 
500xg for 5 minutes and filtered through a 0.45 μm filter (Millipore). T25 flasks of 
HUVECs at 25-30% confluence were infected with 4.5 mL viral supernatant and 
Polybrene (12 μg/mL; Sigma) overnight. Another 4.5 mL of viral supernatant and  
Polybrene (Sigma) were added to HUVECs and infected for 48 h. HUVECs were 
allowed to grow for three days prior to use in invasion experiments. 
Immunoprecipitation 
 In 2D experiments, confluent ECs (3x106) cultured in T75 flasks were treated for 
1 h with or without 1 µM S1P or 40 ng/mLVEGF and bFGF. Cells were placed on ice 
and washed twice with 10 mL cold PBS. Cell pellets were lysed in 1 mL cold lysis 
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 
1X protease inhibitor cocktail (Roche Diagnostics) and 1mM PMSF) and incubated for 
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10 minutes on ice with occasional mixing. Cell lysates were centrifuged at 16,000xg for 
15 minutes at 4°C. Five microliters of protein G-magnetic beads (Invitrogen) were added 
for 1 h at 4°C with agitation to pre-clear cell lysates. Supernatants (1 mL) were 
incubated with 2 µg antisera directed to vimentin, RACK1, or FAK for 18 h at 4°C with 
agitation. Protein G-magnetic beads (10 µL) were added for 2 h at 4°C. Beads were 
washed 6 times with 1 mL lysis buffer without protease inhibitors, eluted in 1% SDS and 
analyzed by Western blotting.  For 3D experiments, 30 gels with 30,000 ECs each were 
collected in 600 µL of cold lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% 
NP40, 0.5% sodium deoxycholate, 1X protease inhibitor cocktail (Roche Diagnostics) 
and 1mM PMSF). Mixtures were incubated for 30 minutes at 4°C with gentle agitation. 
Cell lysates were centrifuged at 16,000xg for 20 minutes at 4°C. Supernatants were 
collected and incubated with protein G-magnetic beads (5 µL) for 1 h at 4°C with 
agitation for preclearing the cell lysates. The remaining steps were performed as above.  
Immunofluorescence and Colocalization Studies 
 Cells were seeded on collagen or fibronectin coated coverslips (20 µg/mL) and 
allowed to grow overnight. In wound assays, cells were wounded with a pipette tip and 
washed twice with M199. Cells were treated with 1 µM S1P or 40 ng/mL growth factors 
(or both) for 1 h, fixed in 4% paraformaldehyde, and rinsed three times in Tris-Glycine 
buffer (0.3% Tris, 1.5% Glycine), permeabilized with 0.5% Triton X-100 for 20 minutes 
with gentle agitation before blocking in buffer containing 0.5% TX-100, 1% BSA and 
1% serum overnight at 4°C. Primary antibodies were added in blocking buffer (1:50) for 
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3 h at room temperature, washed, and incubated with Alexa-488- or -594-conjugated 
secondary antibodies (Molecular Probes, Grand Island, NY) (1:300) in blocking buffer 
for 1 h. After washing, coverslips were mounted and imaged using a Nikon TI A1R 
inverted confocal microscope. For quantification of colocalization, intensity profiles of 
RACK1 (red) and vimentin (green) along randomly-selected lines in the image were 
plotted using NIS-Elements software. Average Pearson’s correlation coefficient from ‘n’ 
number of cells for each treatment group was statistically analyzed. 
Imaging and Quantification of Invasion Density and Distance 
 Top and side views of invading ECs were captured using an Olympus CKX41 
microscope equipped with Q color 3 Olympus camera and 10 X objective. Invasion 
densities were quantified by counting fixed cultures under transmitted light using an 
inverted microscope equipped with eyepieces with a 10 X 10 ocular grid. For each 
condition, atleast three random fields were selected and the number of invading cells per 
high power field (HPF) was counted manually. Data are reported as mean numbers of 
invading cells per HPF (±SD). Invasion length was measured using digital images taken 
from a side view of cultures at 10X magnification using Image-Pro Analyzer 7.0. Data 
are reported as average invasion distance in microns (±SEM). 
Cell Adhesion Assays 
 High binding EIA/RIA 96 well plates (Corning-Costar) were precoated overnight 
with various doses of fibronectin and blocked with 10 mg/mL BSA for 45 minutes. ECs 
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expressing shRNAs directed to β2M, RACK1 and vimentin (30,000 cells per well) were 
incubated at 37°C for 15 minutes before removing unbound cells. Plates were fixed in 
3% formalin for 3 h before staining with 0.1% amido black in 10% acetic acid and 30% 
methanol for 15 minutes. Plates were thoroughly washed and dried before adding 50 µL 
of 2N NaOH per well. The absorbance (595 nm) was read using Victor X3 plate reader 
(Perkin Elmer, Waltham, Massachusetts). 
RESULTS 
Identification of RACK1 as a Regulator of S1P Induced Invasion in ECs 
 The EC invasion assay utilized in this study is a defined 3D model of endothelial 
invasion where robust and rapid invasion responses are triggered by S1P, bFGF, and 
VEGF [45, 143]. To identify intracellular targets of S1P that regulate EC invasion, ECs 
were treated with growth factors only (GF), S1P and growth factors (S1P+GF), or S1P 
and growth factors plus pertussis toxin (S1P+GF+PTX) to inhibit sprouting responses. 
PTX blocks S1P receptor activity by catalyzing ADP-ribosylation of α subunits of 
heteromeric G proteins (G0, Gi, and Gt) thus preventing G proteins from interacting with 
their receptors and interfering with intracellular communication [57]. Dose response 
experiments determined 0.1 ng/mL PTX blocked S1P- and GF- induced invasion (Fig. 
2). Treatment with PTX effectively blocked invasion in ECs to control levels with GF 
alone (Fig. 3A).  Quantification of invasion density showed significantly more sprouting 
with S1P+GF treatment compared to GF alone or S1P+GF+PTX treatment (Fig. 3B).  
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Figure 2. PTX dose response experiment. Invasion experiments were 
established by pre-incubating cells without (Control) or with indicated doses of 
pertussis toxin (PTX) for 20 minutes at 37°C prior to seeding on collagen 
matrices with (B) 0 µM S1P or (A) 1 µM S1P and 40 ng/mL VEGF and bFGF 
(GF). Cultures were fixed in 3% glutaraldehyde and stained with toluidine blue 
prior to quantification. Data represents average number of invading cells per 
standardized field (n=3 fields). 
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Figure 3. Effect of pertussis toxin (PTX) on S1P- and GF- induced EC 
invasion. (A) Photographs illustrating invasion responses (upper panels, top-
view; lower panels, side-view). ECs were treated with 40 ng/mL VEGF and bFGF 
alone (GF), or 1 μM S1P + GF (S1P+GF), or S1P, GF, and 0.1 ng/mL pertussis 
toxin (S1P+GF+PTX). Cultures were fixed in 3% glutaraldehyde at 12.5 h, 
stained with toluidine blue, and photographed. Black arrowheads indicate 
invading cells. Scale bar=50 μm. (B) Quantification of EC invasion density in 
response to various treatments at 12.5 h invasion. Data represents average number 
of invading cells per 1 mm2 field ± SD (n=5 fields, Student’s t-test, *** p<0.001, 
compared to other treatments). 
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Protein lysates from 12.5 h invading EC cultures shown in figure 2A were 
analyzed in two independent proteomic screens designed to dissect downstream 
regulators of S1P signaling in ECs. Protein identification was carried out using two 
search engines; TurboSEQUEST (TQ) and Mascot (M) and the identified target proteins 
were ranked according to their XCorr values (XC scores), where a score above 2.0 is 
indicative of a good correlation. Differential in-gel electrophoresis (proteomic screen 1) 
revealed annexinA2 (ANXA2), RACK1, and vimentin were upregulated with S1P+GF 
treatment compared to S1P+GF+PTX (Table 2). In addition, several proteins were found 
to be downregulated in S1P-induced invasion compared to non-invading ECs (Table 3). 
An independent screen using a distinct approach (Proteomic screen 2) confirmed 
ANXA2 and RACK1 were upregulated with S1P and GF treatment compared to 
S1P+GF+PTX (Table 4). 
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Table 2. List of up-regulated proteins from proteomic screen 1 
 
Spot 
# 
Predicted 
protein match 
TQ 
or 
M 
Calculated 
pI value 
Nominal 
mass 
(Daltons) 
Expression 
change 
Score 
XC 
Sequence 
coverage 
(%) 
760 
Annexin A2 
chain A, 
structure in 
presence of Ca2+ 
ions 
TQ, 
M 
8.32 36631 1.27 
TQ 
260.28, 
M 115 
60 
790 
Annexin A2 
TQ,
M 
7.57 38780 
1.23 
TQ 
170.25, 
M 176 
55 
744 M 1.22 M 184 48 
870 
Receptor for 
activated protein 
kinase C 
(RACK1) 
TQ 7.54 35054 
1.26 
TQ 30.21 11.99 
Actin related 
protein 2/3 
complex, subunit 
2 (ARPC2) 
TQ, 
M 
6.84 34427 
TQ 
18.16, M 
60 
14 
602 Vimentin TQ 5.06 53619 1.20 
TQ 
128.22 
18 
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Table 3. List of down-regulated proteins from proteomic screen 1 
 
Spot 
# 
Protein match 
TQ 
or 
M 
Calculated 
pI value 
Nominal 
mass 
(Daltons) 
Expression 
change 
Score 
XC 
Sequence 
coverage 
(%) 
236 
HSP70 protein 8, 
isoform 1 
TQ 5.37 70854 
-1.22 
TQ 20 50 
HSP70 protein 8, 
isoform 2 
TQ 5.37 53484 
TQ 
160 
37.73 
HSP70 protein 8, 
isoform 1 variant 
M 5.28 71083 M 124 50 
HSP70 protein 1A 
TQ, 
M 
5.37 69995 
TQ 48, 
M 146 
6.24 
955 
Lamin A/C TQ 8.54 70619 
-1.22 
TQ 60 9 
HSP 27 TQ 5.97 22768 TQ 40 23.14 
824 Annexin A5 TQ 4.5 35915 -1.25 
TQ 
70.3 
35 
808 Otubain 1 TQ 4.7 31264 -1.26 
TQ 
50.25 
24.35 
672 
Vimentin fragment 
TQ 
4.91 53619 
-1.30 
TQ 
124 
25.11 
668 TQ, 
M 
-1.40 
TQ 
140, M 
134 
18.24 
705 TQ -1.53 
TQ 
100 
9 
446 
ATP synthase, 
mitochondrial F1 
complex β subunit 
TQ ND 56524 -1.36 
TQ 
130 
39 
89 
Tumor rejection 
antigen  
TQ, 
M 
4.76 92696 
-1.49 
TQ 
280 
18 
HSP 94B M 5.14 46343 M 46 18 
1090 
Stimulator of TAR 
RNA binding 
M 7.52 58316 
-1.85 
M 74 18 
Chaperonin 
containing TCP1, 
δ subunit 
TQ 7.75 57887 
TQ 
70.22 
15.03 
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Table 4. List of up-regulated proteins from proteomic screen 2 
 
Predicted protein match Score XC Sequence coverage (%) Accession number 
Annexin A2 100.24 27.14 119574085.0 
Receptor for activated C 
kinase 1 (RACK1) 
50.23 12 30584373.0 
Lamin B2 60.19 11.33 119589784.0 
Peroxiredoxin 1 40.19 19.59 55959887.0 
 
 
 
Upregulation of ANXA2, RACK1, and vimentin were confirmed in separate 
experiments using western blotting (Fig. 4A). Although we observed upregulation of 
ARPC2 (Table 2), a requirement for ARPC2 in S1P- and GF-induced EC invasion was 
not confirmed (data not shown), thus ARPC2 was not investigated further. ANXA2, 
RACK1 and vimentin protein expression levels observed with PTX treatment were 
consistent with GFs alone (Fig. 4). Quantification of the data revealed significant 
upregulation of ANXA2, RACK1, and vimentin with S1P+GF treatment compared to 
GF alone or S1P+GF+PTX treatment (Fig. 4B). No change in β2M levels were observed 
in all treatment groups. Our laboratory has investigated the role of ANXA2 in separate 
studies and found that ANXA2 complexed with VE-cadherin, upstream of Akt 
activation, to regulate EC sprouting [67], and thus ANXA2 was not investigated in this 
study. Because RACK1 has been implicated in cell migration and blood vessel formation 
[128], and we have previously identified a requirement for vimentin [66], we focused 
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our investigation on better understanding the interplay between RACK1 and vimentin in 
EC invasion responses. 
 
Figure 4. Western blot analysis to verify upregulation of identified proteins. 
(A) Verification of annexin A2 (ANXA2), vimentin (VIM) and receptor for 
activated C kinase (RACK1) protein upregulation. ECs treated with GF, S1P+GF 
or S1P+GF+PTX were allowed to invade for 12.5 h prior to preparing cell 
extracts. Antisera specific to ANXA2, VIM, RACK1 and β2M were used for 
Western blot analyses. (B) Quantification of protein expression from Western 
blots using Image J software and normalized to β2M. The results represent 
average values normalized to β2M ± SD in arbitrary units (a.u.) from three 
independent experiments (Students t-test, * p<0.05, compared to all other 
treatments).  
 
 
 
RACK1 Was Required for EC Invasion 
 Recombinant lentiviruses from three individual shRNA sequences targeted 
against RACK1 (shRACK1-1, -2 and -3) and two shRNA sequences specific to β2-
microglobulin (β2M, shβ2M-1 and -2) were utilized to transduce ECs. To test 
knockdown efficiency at the mRNA and protein level, PCR analysis using primers 
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specific to RACK1, β2M and GAPDH revealed efficient silencing of RACK1 mRNA 
with shRACK1-1 and shRACK1-2 treatment (Fig. 5A). Western blot analyses of cell 
lysates revealed knockdown of RACK1 protein that were consistent with mRNA levels 
(Fig. 5A and B). β2M control also showed efficient knockdown with shβ2M-1 and -2 
treatment of  β2M mRNA (Fig. 5A) and protein (Fig. 4B). To test specificity of shRNA 
mediated knockdown of RACK1 and β2M, expression levels of other molecules known 
to regulate EC sprouting such as vimentin, VE-cadherin, filamin A (FLNA) and FAK, 
were analyzed (Figure 5A and B). No significant changes in mRNA or protein levels of 
GAPDH, ANXA2, FAK, VE-cadherin, FLNA or vimentin were seen with shβ2M and 
shRACK1 treatment (Fig. 5A and B).  To test the effect of RACK1 silencing on S1P- 
and GF- mediated endothelial invasion, ECs were transduced separately with 
recombinant lentiviruses shRACK1-1 and -2, non-transfected ECs (WT), ECs 
transfected with packaging vectors only (MOCK), or shRNA sequences directed against 
β2-microglobulin (shβ2M) were used as controls. Photographs of invading cultures 
illustrated that knockdown of RACK1 interfered with endothelial invasion responses 
stimulated by S1P and GF (Fig. 5C). Western blot analyses of extracts collected from 
invading cultures showed selective knockdown of RACK1 and β2M with respective 
shRNAs (Fig. 5D). Quantification of invasion density revealed a significantly decreased 
number of invading cells with RACK1 depletion as compared to shβ2M, WT and 
MOCK controls (Fig. 5E). These results demonstrated that RACK1 was required for 
S1P- and GF- stimulated EC invasion in 3D collagen matrices. 
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Figure 5. RACK1 knockdown decreased invasion responses in ECs.  (A) Non-
transduced ECs (WT), or ECs transduced with lentiviruses delivering shRNA 
directed to β2-microglobulin (shβ2M-1 and -2) or RACK1 (shRACK1-1, -2 and -
3) were utilized to generate RNA, cDNA, and RT-PCR reactions  using RACK1-, 
β2M-, GAPDH-, ANXA2-, FAK-, VE-Cadherin-, VIM-, and Filamin A- specific 
primer sets. (B) Cell lysates from treatment groups as in A were analyzed by 
Western blotting using RACK1, β2M-, GAPDH-, ANXA2-, FAK-, VE-cadherin-, 
VIM-, filamin A-, and tubulin-specific antisera. (C) Non-transduced ECs (WT), 
or ECs transduced with lentiviruses delivering shRNA directed to β2-
microglobulin (shβ2M-1) or RACK1 (shRACK1-1 and -2) were tested in 3D 
invasion assays using S1P+GF. Photographs to illustrate the invasion responses 
(top-view, upper panel; side-view, lower panel). Scale bar=50 μm. (D) Western 
blot analyses of whole cell lysates to verify β2M and RACK1 protein suppression 
using RACK1-, β2M-, and tubulin- specific antisera. Quantification of (E) 
invasion density and (F) invasion distance at 20 h of invasion. Data in (E) 
represent average number of invading cells per 1 mm2 field ± SD (n=3 fields, 
Students t-test, **p<0.01, compared to shβ2M). Data in (F) represent average 
length of structures ±SEM (n>80 cells; Students t-test, **p<0.01, ***p<0.001 
compared to shβ2M). Representative experiment shown (n=4). 
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Figure 5. Continued  
 
 
To test whether RACK1 rescue would restore invasion responses decreased by 
RACK1 silencing, GFP-RACK1 constructs were mutated using site-directed 
mutagenesis to alter the shRACK1-1 target site (R3). GFP and R3 constructs were 
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overexpressed in ECs treated with lentiviruses delivering shRNA targeted to β2M and 
RACK1 and utilized in invasion experiments along with non-transfected ECs (WT) (Fig 
6A). Western blot analyses of cell lysates showed successful knockdown of RACK1 and 
β2M (Fig. 6B). Also, expression of R3 rescue construct (~65 kDa) was successfully 
detected in shRACK1+R3 treatment group with GFP antisera (Fig. 6B).  Quantification 
of invasion density revealed no significant impairments in invasion responses compared 
to WT when transducing with shβ2M+GFP, indicating multiple transductions had no 
negative effects. A significant decrease in sprouting was seen with shRACK1+GFP 
compared to shβ2M+GFP or WT control (Fig. 6C). Furthermore, expression of R3 
rescue construct with RACK1-specific shRNA (shRACK1+R3) resulted in a slight but 
significant increase of invasion density (Fig. 6C) and invasion distance (Fig. 6D) 
compared to shRACK1+GFP. Thus, rescuing with the RACK1 expression with R3 GFP-
RACK1 in shRACK1-1 expressing ECs increased the number and length of sprouting 
ECs compared to GFP control, supporting a requirement for RACK1 in mediating 
endothelial sprouting responses.  
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Figure 6. RACK1 rescue partially restores sprouting responses and invasion 
distance reduced by RACK1 silencing. ECs were transduced with lentiviruses 
delivering shRNA directed to β2M (shβ2M) or RACK1 (shRACK1) before being 
transduced with lentiviruses delivering enhanced green fluorescent protein (GFP) 
control or R3 (GFP-RACK1 rescue construct). (A) Photographs of a side view 
illustrating invasion responses. Scale bar=50 µm. (B) Western blot analyses of 
whole cell lysates probed with RACK1-, GFP-, β2M- and tubulin-specific 
antisera.  Arrow indicates expression of R3 (65kDa) construct. (C) Quantification 
of invasion density at 22 h. Data represents average number of invading cells per 
1mm2 field ± SD (n=4 fields, one-way ANOVA). (D) Quantification of invasion 
distance from EC monolayer to the tip of invading structures. The results 
represent average values ± SEM (n>100 sprouts, one-way ANOVA). (C and D) 
Means with the same letter are not significantly different. 
 
 
 
 
 
  
42 
 
 
RACK1 Depletion Decreased FAK Activation  
 RACK1 is proposed to act as a scaffold protein and plays a role in various 
cellular processes including cell migration [121, 123, 144]. Most functions of RACK1 
associated with cell adhesion, spreading and migration are linked to its ability to 
associate with FA proteins such as FAK and regulate its activity [123, 126, 145, 146]. 
These studies guided us to investigate whether RACK1 affected FAK activity during EC 
sprouting in collagen matrices. ECs were transduced with recombinant lentiviruses 
expressing shRACK1 or shβ2M and utilized in invasion assays. Whole cell extracts were 
collected from invading cultures at 0, 2, and 3 h and analyzed by western blotting. We 
observed that RACK1 and β2M were successfully silenced (Fig 7A). In addition, FAK 
activation, indicated by an autophosphorylation event at tyrosine residue 397 (Y397), 
was decreased at 2 h in RACK1 depleted ECs compared to shβ2M controls. However, 
overall expression of total FAK was not affected. Tubulin and GAPDH loading controls 
remained constant (Fig. 7A). FAK phosphorylation significantly decreased in ECs 
expressing shRACK1 compared to shβ2M at 2 h of invasion (Fig. 7B). These results 
suggested that RACK1 was required for FAK activation in ECs. 
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Figure 7. Depletion of RACK1 reduced FAK activation. (A) ECs expressing 
shRNA directed to β2M (shβ2M) or RACK1 (shRACK1) were allowed to invade 
for the time points indicated. Whole cell lysates were prepared and analyzed by 
Western blot analysis using polyclonal antisera directed to phosphorylated FAK 
(pFAK) (Y397) and β2M, and monoclonal antibodies directed to total FAK, 
RACK1, and tubulin. (B) Intensity levels for pFAK (Y397) and total FAK were 
normalized to tubulin using Image J software. Ratios of normalized pFAK and 
FAK were plotted ± SD in arbitrary units (a.u.) from three independent 
experiments (Student’s t-test, * p<0.05, compared to shβ2M control). 
 
 
 
FAK Activation Occurred during EC Invasion 
 Because RACK1 knockdown decreased FAK activation, we investigated whether 
FAK activity was required for endothelial sprouting. ECs treated with FAK inhibitor 
(FI), which selectively blocks FAK phosphorylation at Y397, were allowed to invade 
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collagen matrices overnight. Quantification of invasion responses indicated FI treatment 
dose-dependently inhibited invasion, indicating FAK activation was required for 
endothelial invasion (Fig 8A). No adverse effects on cell monolayers or cell viability 
were observed with blocking FAK activity (data not shown). Western blot analysis 
confirmed a dose-dependent decrease in Y397 phosphorylation (Fig. 8B) with FI 
treatment, correlating with a decrease in EC sprouting (Fig 8A). Representative side-
view images of sprouting EC cultures treated with 0, 5 and 10 µM FI illustrated partial 
and complete inhibition of sprouting at 5 and 10 µM dose of FI, respectively (Fig. 8C). 
These results demonstrated a requirement for FAK activation during S1P- and GF- 
stimulated endothelial sprouting. 
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Figure 8. EC invasion required FAK activation. (A) ECs were pre-incubated 
with FAK inhibitor (FI) at the concentrations indicated for 20 minutes at 37°C 
prior to seeding on collagen matrices. ECs were allowed to invade for 20 h with 
S1P+GFs. Samples were fixed in 3% glutaraldehyde and stained with toluidine 
blue. Data represents average numbers of invading cells per 0.25 mm2 field ± SD 
(n=3, Student’s t-test, * p<0.05, ** p<0.01, *** p<0.001, as compared to 0 μM FI 
treatment). (B) Whole cell extracts from invading cultures from (A) at 2 h with 
indicated FI concentration were immunoblotted with antisera directed against 
pFAK (Y397), FAK, tubulin, and GAPDH. (C) Representative photographs of a 
side view of invasion (24 h) with 0, 5 and 10 μM FI treatment. Scale bar=50 μm. 
 
 
 
Vimentin Regulated FAK Expression in ECs 
 Proteomic studies demonstrated that full length 60 kDa vimentin was upregulated 
in invading versus non-invading ECs (Table 2), and Burgstaller et al.  have suggested 
that networking and anchorage of vimentin intermediate filaments at FAs resulted in cell 
shape changes, polarization and prolonged lifespan of FAs in mouse fibroblasts [129].  
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We have previously shown that vimentin was required for endothelial sprouting [66]. 
Because of the link between vimentin and FA regulation [129] and a known requirement 
for vimentin in EC sprouting [66], we tested whether vimentin regulated FAK in S1P- 
and GF-stimulated invasion.  ECs transduced with recombinant lentiviruses expressing 
short hairpin RNAs directed against vimentin (shVIM) or β2M (shβ2M) were allowed to 
invade collagen matrices. Whole cell extracts collected from invading cultures at 0, 2, 
and 3 h were analyzed by western blotting. We observed a decrease in total and 
phosphorylated FAK levels with vimentin knockdown compared to shβ2M controls (Fig. 
9A). Quantification of western blots revealed a significant difference in the expression of 
total FAK at all time-points between shVIM and shβ2M expressing ECs (Fig. 9B). These 
data suggested that vimentin regulated FAK expression. We reported calpain-dependent 
vimentin cleavage occurred predominantly in response to GF stimulation and that 
vimentin solubility was altered during EC invasion [66]. To determine whether vimentin 
solubility affected FAK expression, we analyzed invading cultures treated with a calpain 
inhibitor. A decrease in FAK expression was not observed when ECs were treated with 
calpain inhibitor-III, which specifically blocked calpain dependent vimentin cleavage 
(Fig. 10), suggesting that the solubility state of vimentin did not affect FAK expression 
during endothelial sprouting. 
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Figure 9. Vimentin regulated FAK expression in ECs. (A) ECs were 
transduced with shRNA directed to β2M (shβ2M) and vimentin (shVIM) and 
placed in invasion assays in the presence of S1P+GF. Whole cell lysates were 
prepared at indicated time points. Western blot analyses were conducted using 
polyclonal antisera directed to phospho-FAK (Y397) and β2M, as well as 
monoclonal antisera directed to total FAK, tubulin, GAPDH and vimentin. (B) 
Quantification of FAK protein expression using Image J software and normalized 
to GAPDH. The results represent average values ± SD in arbitrary units (a.u.) 
from three independent experiments (Students t-test, * p<0.05, compared with 
shβ2M expression). 
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Figure 10. Calpain inhibition does not affect FAK expression or activation. 
ECs pre-incubated with or without 100 μM CI-III were allowed to invade 
collagen matrices for 6 h. Whole cell extracts were prepared at indicated time-
points and immunoblotted with antisera directed against FAK, vimentin, actin and 
tubulin. 
 
 
 
RACK1 Complexed with Vimentin and GFs Enhanced this Interaction 
 The above data show RACK1 and vimentin regulate FAK activation and 
expression. Immunoprecipitation experiments revealed vimentin complexed with 
RACK1 (Fig. 11A). RACK1 also immunoprecipitated with vimentin antisera (Fig. 11B), 
indicating that a complex containing RACK1 and vimentin was formed in EC 
monolayers stimulated with S1P and GFs. To test whether this association was 
stimulated by individual pro-angiogenic stimuli, EC monolayers were untreated 
(control), treated with 1 µM S1P, or treated with a combination of 40 ng/mL VEGF and 
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bFGF (GF) for 1 h. Immunoprecipitations were performed by incubating lysates with 
RACK1 specific antisera, and eluates were probed for vimentin and RACK1. 
Interestingly, we observed an increase in RACK1-vimentin association with GF (but not 
S1P) stimulation, while equivalent amounts of RACK1 were immunoprecipitated in all 
conditions (Fig. 11C). Data quantified from three independent experiments indicated a 
significant increase in immunoprecipitated vimentin with GF treatment, as compared to 
the starting material (Fig. 11D). To confirm GF-mediated increase in co-localization, 
ECs seeded on collagen coated glass coverslips were serum starved for 1 h and not 
treated (Control) or treated with S1P or GF and stained with RACK1- and vimentin- 
specific antisera (Fig. 11E). Quantification of colocalization in each treatment group 
confirmed that GFs significantly increased overlap when compared to control or S1P 
treatment (Fig. 11F). These results support that GFs enhanced complex formation 
between RACK1 and vimentin.  
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Figure 11. Growth factor stimulation enhanced RACK1-vimentin complex 
formation. (A) ECs were cultured in T75 flasks for 3 days without replenishing 
growth media and stimulated with S1P+GF for 1 h. Immunoprecipitations were 
performed using monoclonal RACK1 antibodies or isotype controls (IgG) and 
probed for vimentin and RACK1 using Western blot analyses. (B) Reverse 
immunoprecipitations were performed using a polyclonal vimentin antibodies or 
isotype controls (IgG) and probed for RACK1 and vimentin using Western blot 
analyses. (C) ECs cultured in T75 flasks for 3 days and stimulated with nothing 
(control), 1 μM S1P (S1P), or 40 ng/mL GF (GF) for 1 h. Immunoprecipitations 
were performed using monoclonal RACK1 antibodies or isotype controls (IgG). 
Eluates were probed with vimentin- and RACK1- specific antisera using Western 
blotting. (D) Quantification of co-precipitated vimentin normalized to starting 
material from Western blots using Image J software. The results represent average 
values ± SD in arbitrary units (a.u.) from three independent experiments 
(Student’s t-test, **p<0.01, compared to control). (E) ECs seeded on glass 
coverslips were serum-starved for 1 h and treated without (Control), with 1 μM 
S1P (S1P), or with 40 ng/ml GFs (GF) for 1 h. Following paraformaldehyde 
fixation, cells were stained with monoclonal anti-RACK1 or polyclonal anti-
vimentin antibodies and detected with species-specific secondary antibodies 
conjugated to Alexa Fluor 594 and Alexa Fluor 488. Images were collected using 
Nikon A1 confocal laser microscopy. Scale bar=5 μm.  (F) Quantification of 
RACK1 (red) and vimentin (green) co-localization using Pearson’s correlation 
coefficient. The results represent average values ± SD from each treatment group. 
n = number of cells per treatment group (one-way ANOVA with Bonferroni's 
multiple comparison post-hoc test, * p<0.05, compared to control). 
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Figure 11. Continued 
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Vimentin Association with FAK Required RACK1 
 Thus far our data showed that downstream of pro-angiogenic signals, RACK1 
and vimentin complexed to regulate FAK expression and activation. To test whether 
FAK was a part of this complex, as well as whether S1P and GF stimulation enhanced 
formation of the complex, lysates from ECs invading 3D collagen matrices treated 
without (-) or with (+) S1P and GF were collected for immunoprecipitation experiments. 
We observed that increased RACK1 and FAK co-immunoprecipitated with vimentin 
with S1P and GF stimulation (Fig. 12A). Reverse immunoprecipitations using RACK1- 
(Fig. 12B) and FAK-specific antisera (Fig. 12C) were performed to confirm these 
interactions were enhanced by S1P and GF treatment. Thus, conditions that stimulate EC 
invasion enhanced the formation of a RACK1, vimentin, and FAK complex in 3D 
cultures. Based on these data, we next tested whether FAK activation was needed to 
stabilize the complex. Interestingly, FAK inhibition (FI) did not alter complex formation 
between vimentin, RACK1, and FAK (Fig. 13). Vimentin binding to FAK remained 
unaltered with FI, and FAK and vimentin similarly bound RACK1 (Fig 13), which 
suggested that association of RACK1 and vimentin with FAK was independent of FAK 
activation. To further investigate the role of RACK1, we tested whether RACK1 
silencing altered complex formation. Knockdown of RACK1 and β2M protein levels 
were confirmed using western blot analyses (Fig. 12D). RACK1 knockdown resulted in 
decreased complex formation between full length vimentin (60 kDa) and FAK compared 
to β2M knockdown (Fig. 12E). Quantification of data from three independent 
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experiments indicated a significant decrease in vimentin and FAK complex formation 
with RACK1 knockdown (Fig. 12F). Taken together, these results indicated that the 
scaffold protein RACK1 was needed to maintain complex formation between vimentin 
and FAK.  
 
Figure 12. RACK1, vimentin, and FAK complex formation is enhanced 
during EC invasion. Confluent flasks (75cm2) of ECs were serum starved for 2 
h, trypsinized and placed in invasion assays in the absence (-) or presence of 
S1P+GF (+) for 3 h prior to lysate preparation. Immunoprecipitations were 
performed using polyclonal antisera directed to (A) vimentin, (B) RACK1 and 
(C) FAK, along with matched isotype controls (IgG). Eluates (A-C) were probed 
for vimentin (VIM), FAK, and RACK1 using Western blot analyses and are from 
one representative experiment (n=3). (D-F) ECs were transduced with lentiviruses 
delivering shRNAs directed to RACK1 (shRACK1) or β2M (shβ2M) and allowed 
to invade collagen matrices for 3 h prior to cell lysis and immunoprecipitation. 
(D) Western blot analyses of starting material to verify successful silencing of 
β2M and RACK1 proteins. (E) Immunoprecipitations were performed using a 
monoclonal FAK antibody or isotype control (IgG) and probed for FAK and 
vimentin (VIM) using Western blot analyses. (F) Quantification of co-precipitated 
vimentin normalized to input material from Western blots using Image J software. 
The results represent average values ± SD in arbitrary units (a.u.) from three 
independent experiments (Student’s t-test, *p<0.05, compared with shβ2M 
control). 
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Figure 12. Continued 
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Figure 13. Inhibition of FAK activity does not alter complex formation 
between RACK1, VIM and FAK. Invasion experiments were established by 
pre-incubating cells with 0 (CON) or 10 µM FI (FI) for 20 minutes at 37°C prior 
to seeding on collagen matrices. ECs were allowed to attach the collagen matrices 
and invade for 3 h, prior to cell lysis and immunoprecipitations. ECs used for 
immunoprecipitation with IgG control were treated with 0 µM FI. (A) 
Immunoprecipitations were performed using a monoclonal FAK antibody or 
isotype control (IgG) and probed for pFAK (Y397), FAK and vimentin (VIM) 
using Western blot analyses. (B) Immunoprecipitations were performed using a 
monoclonal RACK1 antibody or isotype control (IgG). Eluates were probed for 
RACK1, FAK and vimentin (VIM) using Western blot analyses. 
 
 
 
Knockdown of Vimentin and RACK1 Decreased Cell Attachment and Focal Adhesion 
Formation  
 We next tested the consequences of vimentin knockdown on cell adhesion, which 
has been linked to focal adhesion formation [147]. Endothelial cells expressing shRNA 
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directed to β2M or vimentin were allowed to attach to wells coated with increasing doses 
of fibronectin. These experiments were conducted rapidly (15 minutes) to determine 
whether vimentin silencing altered cell attachment using an established method [148].   
Endothelial cell attachment to fibronectin occurred rapidly and was dose-dependent. 
However, cells expressing shRNA directed to vimentin (shVIM) exhibited decreased 
attachment compared to shβ2M controls (Fig. 14A). Western blot analyses confirmed 
successful knockdown of both vimentin and β2M (Fig. 14B). These data demonstrate 
that decreasing vimentin levels in ECs reduced cell attachment (Fig. 14A), which 
coincides with decreased FAK expression (Fig. 9). Similar experiments conducted with 
ECs expressing shRNA directed to RACK1 showed decreased attachment to fibronectin 
compared to shβ2M controls (Fig. 14C). Western blot analyses confirmed successful 
knockdown of both RACK1 and β2M (Fig. 14D). In addition to cell attachment, focal 
adhesion formation (visualized through pFAK Y397 and vinculin staining) was also 
decreased in ECs expressing shVIM and shRACK1 compared to shβ2M controls. While 
large, organized focal adhesions were observed in shβ2M controls, as indicated by 
vinculin and pFAK co-staining (Fig. 14E), smaller and less distinct structures were seen 
with shVIM and shRACK1 expression. 
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Figure 14. Vimentin silencing reduced EC adhesion responses. ECs were 
transduced with shRNA directed to (A) β2M (shβ2M) and vimentin (shVIM) or  
(C) shβ2M and shRACK1  for 4 days before being plated on wells coated with 
increasing amounts of fibronectin at the doses indicated for 15 min. Absorbance 
values (595 nm) represent relative levels of cell attachment. Experiments are 
representative of 4 independent experiments. (B) Western blot of cell extracts 
probed with antisera directed to β2M, α-tubulin and vimentin from experiment in 
panel A.  (D) Western blot of cell extracts probed with antisera directed to β2M, 
α-tubulin and RACK1 from experiment in panel C. (E) Indirect 
immunofluorescent staining of ECs expressing shβ2M, shVIM, and shRACK1 
using monoclonal antibody directed against pFAK (Y397) and vinculin. Scale 
bar=10 µm  
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Figure 14. Continued  
 
 
DISCUSSION 
In this study, we performed a proteomic analysis to determine changes in protein 
expression associated with sprouting angiogenesis. The 3D model used in this study 
incorporated S1P with angiogenic growth factors VEGF and bFGF to stimulate robust 
EC sprouting [45].  The assay system mimicked a wound environment where S1P 
combined with VEGF and bFGF stimulated new blood vessel formation [16]. In this 
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study, we report a novel mechanism to control sprouting angiogenesis in 3D collagen 
matrices. Proteomic analyses from two independent screens showed upregulation of 
receptor for activated C kinase 1 (RACK1) in invading ECs, suggesting a crucial role for 
RACK1 downstream of S1P and GF signaling. Our findings suggest that RACK1 
regulated sprouting through association with the major intermediate filament (IF) 
protein, vimentin and consequent regulation of FAK. 
 Our results are the first to demonstrate a complex formation between RACK1 
and vimentin during endothelial sprouting. The WD-repeat protein, RACK1, is a highly 
conserved cellular adaptor protein with a seven-bladed β-propeller structure. This unique 
structure facilitates binding with a variety of proteins either directly or as a part of a 
larger complex [149-156].  RACK1 also shuttles proteins to specific cellular sites, 
modulating enzymatic activity of its binding partners and stabilizing protein interactions. 
We find here that GF stimulation increased RACK1 complex formation with full length 
vimentin during EC sprouting. The intermediate filament protein vimentin is involved in 
many important physiological functions such as distribution of organelles, signal 
transduction, cell polarity and gene regulation [157-159]. Previous work from our 
laboratory demonstrated a direct requirement of vimentin during angiogenic sprouting. 
Soluble vimentin, resulting from calpain mediated cleavage downstream of GF 
stimulation facilitated MT1-MMP membrane translocation and successful endothelial 
sprout formation [66]. We find here full length vimentin (60 kDa) regulated EC invasion 
through a unique pathway involving RACK1 and FAK.  
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 The major focal kinase protein FAK has been established as a key mediator in 
cell migration and endothelial morphogenesis. FAK conditional knockout mice exhibited 
severe cardiac defects, ventricular hypertrophy and significantly attenuated chemotaxis 
in isolated cardiomyocytes resulting in embryonic lethal phenotype [140, 141]. Deletion 
of FAK specifically in ECs resulted in defective angiogenesis in embryos, yolk sacs and 
placenta, impaired vasculature and associated hemorrhage, edema and developmental 
delay [142]. Similar studies by Braren et al. revealed that FAK depletion in ECs resulted 
in distinctive and irregular embryonic vasculature with reduced vessel growth and vessel 
regression resulting in lethality between days E10.5 and E11.5. ECs derived from 
mutants exhibited aberrant lamellipodial extensions, altered actin cytoskeleton, and non-
polarized cell movement [139]. These data supported a crucial role for FAK in cardiac 
and vascular morphogenesis and in regulation of EC survival and morphology. In 
agreement with these data, we observed that blocking FAK activation completely 
inhibited sprouting in ECs.  
 Our data also further investigated a connection between vimentin filaments and 
FAK, and to the best of our knowledge are the first to show that vimentin complexed 
with FAK. Numerous studies have established that vimentin intermediate filaments 
terminate at focal contacts [160, 161]. In fibroblasts, tethering of vimentin filaments to 
FAs decreased turnover rate and increased stabilization [129]. Further, vimentin 
regulated focal contact assembly and helped stabilize cell-matrix adhesions in ECs 
subjected to shear stress [130]. FAK is an integral component of FAs and functions to 
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assemble focal contacts in response to integrin clustering by ECM engagement [136, 
137], as well as regulate focal adhesion turnover [162]. Our data showed that vimentin 
was required to maintain FAK expression and activity, which is consistent with data 
showing loss of vimentin correlated with decreased focal contact size and stability [129, 
130].  Fitting with these data, loss of vimentin in endothelial cells and mouse dermal 
fibroblasts attenuated cell adhesion responses.                                                                                                                                                                                                                                                    
 Vimentin depletion resulted in attenuation of phosphorylated and total FAK 
levels in ECs. Interestingly, we did not observe attenuated levels of FAK when blocking 
vimentin cleavage with a calpain inhibitor suggesting that the cleavage state of vimentin 
had no bearing on FAK expression levels. To our knowledge this is the first report to 
show that vimentin controlled FAK expression in ECs. These data have important 
implications in control of cell-matrix interactions during EC sprouting, and these 
findings help explain the ability of vimentin to control FA size and stability. 
 We show here that RACK1 and vimentin complexed with FAK. Furthermore, we 
found that blocking FAK activation did not change the dynamics of this complex 
indicating that formation of the complex did not require FAK activation. Our results 
indicated that vimentin and RACK1 were required to maintain expression and activation 
of FAK, which was crucial for successful sprouting. Since RACK1 is proposed as a 
scaffold protein, its functions are commonly ascribed to its ability to associate and 
stabilize multiple protein interactions. We therefore tested the effect of RACK1 
depletion on vimentin-FAK interaction. We showed here for the first time that binding 
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between vimentin and FAK was RACK1-dependent.  We found significantly decreased 
association between full length vimentin filaments and FAK with RACK1 knockdown. 
These findings reveal a novel scaffold function of RACK1 in stabilizing complex 
formation between vimentin and FAK, and suggest that RACK1 may assist in tethering 
of vimentin filaments to FA complexes [129, 161]. 
 In conclusion, we have demonstrated that RACK1 and vimentin are upregulated 
in sprouting versus quiescent ECs. RACK1, vimentin, and FAK form a complex during 
endothelial sprout formation in 3D collagen matrices, and all of these molecules are 
present in caveolin-enriched microdomains in endothelial cells [163]. FAK [164, 165], 
RACK1 [128, 166, 167], and vimentin [168, 169] are upregulated during tumor 
formation and progression. Since expression of all these molecules is altered during 
malignant disease, this pathway may regulate invasive, metastatic cell behavior. Our 
data provide novel insights into the role of RACK1 during endothelial invasion in 3D 
collagen matrices downstream of S1P signaling.  
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CHAPTER III 
HIC-5 MEDIATED ENDOTHELIAL SPROUTING BY REGULATING FOCAL 
ADHESION KINASE AND A KEY SURFACE METALLOPROTEINASE 
 
INTRODUCTION 
Hic-5 (55 kDa) belongs to the paxillin family of focal adhesion adaptor proteins 
which also includes paxillin and leupaxin [170]. Hic-5 was originally discovered as a 
cDNA clone induced by hydrogen peroxide (H2O2) or transforming growth factor β 
(TGFβ) and thus named hydrogen peroxide inducible clone 5 (Hic-5) [171]. The 
structure of Hic5, which shares significant homology with paxillin, consists of four LD 
(Asp and Leu rich) domains at the N-terminus and four LIM (Lin11, Isl-1 & Mec-3) 
domains at the C-terminus. Both LD and LIM are protein-protein interacting domains, 
thus Hic-5 and its family members provide multiple proteins with interfaces to mediate 
interaction and co-operation, downstream of extracellular matrix (ECM) engagement 
[172, 173]. Hic-5 is known to interact with FAK [174], vinculin [175], paxillin [175], c-
src kinase (Csk) [176], protein tyrosine kinase 2 β (PYK2) [170], and Arf GAP1 (GIT) 
[177] via its N terminal LD domains. The LIM domains at the C-terminus of Hic-5 
mediate binding to PTP-PEST [178] and Hsp27 [179]. Oxidative stress induces 
translocation of Hic-5 into the nucleus wherein it acts as a transcriptional co-activator 
[180-182]. Thus, Hic-5 is a mobile scaffold protein that interacts with several proteins at 
FA sites as well as within the nucleus.  
  
64 
 
 
Hic-5 is expressed in ECs [183] and although Hic-5 knockout mice appeared 
normal and were fertile, subsequent studies revealed defective recovery following 
vascular injury of the femoral artery [184]. Studies in bovine pulmonary aortic ECs 
(BPAECs) revealed that Hic-5 was recruited to focal adhesion sites and pseudopodia 
upon lysophosphatidic acid (LPA) stimulation [185]. Similar observations were reported 
in breast cancer cells, where Hic-5 localized to invadopodia in response to TGFβ [186]. 
Accumulating evidence from recent studies has established a link between Hic-5 and cell 
migration. siRNA-mediated Hic-5 silencing reduced VEGF-mediated migration 
responses in ECs [187] and fibronectin-mediated migration of mouse kidney epithelial 
cells [188]. Hic-5 depletion or expression of Hic-5 mutants that failed to localize to FAs, 
decreased BPAEC migration in the presence of LPA [185]. Studies in breast cancer cells 
by Deakin and Turner showed that Hic-5 silencing induced an amoeboid morphology in 
tumor cells and attenuated integrin-mediated adhesions, migration, invasion, and tumor 
cell metastasis [175]. In addition, recent findings by Pignatelli and colleagues 
demonstrated that Hic-5 depleted tumor cells displayed reduced invasion and matrix 
degradation that was rescued by GFP-Hic-5 expression [186]. Altogether, these studies 
suggest that Hic-5 may be important for endothelial cell migration as well as tumor cell 
invasion, adhesion formation and matrix degradation. However, the role for Hic-5 in 
regulating sprouting responses during angiogenesis remains undetermined. Whether or 
not the role of Hic-5 is distinct in ECs is also unclear.    
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Membrane-type matrix metalloproteinases (MT-MMPs) are widely known to 
mediate ECM breakdown to facilitate cell migration and invasion in 3D matrices [189-
192]. Several studies have reported that MT1-MMP (or MMP14) is required for 
angiogenic sprouting and lumen formation in ECs [192-196]. During tumor cell 
migration, MT1-MMP is enriched in invadopodia, which are defined as dot-shaped 
actin-rich membrane protrusions that extend into the 3D ECM surroundings [189, 197]. 
Although tumor cell invasion and endothelial sprouting are known to be MT1-MMP-
dependent, the precise molecular mechanisms that regulate its membrane translocation 
and activity remain poorly understood. Focal adhesion kinase (FAK) is a major kinase 
protein associated with focal adhesions. FAK is tyrosine phosphorylated upon ECM 
engagement and integrin assembly. Activated FAK recruits and phosphorylates several 
other proteins at focal adhesions to promote focal adhesion growth, maturity, turnover, 
cytoskeletal rearrangement, and cell migration [136-138]. FAK has been extensively 
studied in angiogenesis and cardiac morphogenesis [139-142, 198, 199]. Although FAK 
is present in FAs [200], it has also been implicated in regulating invadopodia [201-203]. 
FAs have been implicated as potential sites for MT1-MMP-dependent matrix 
degradation [204, 205]. Crosstalk between FAK and MT1-MMP has been reported in 
tumor cells, where ECM degradation by MT1-MMP promoted FA stability and cell-
matrix adhesion turnover to direct cell migration [204, 206]. Additional studies 
demonstrated that FAK promotes cell-surface localization of MT1-MMP by disrupting 
endophilin A2- dependent endocytosis [207]. In addition, recent data have indicated that 
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successful association between MT1-MMP and FAK is required for optimal MT1-MMP 
activity and successful matrix degradation at these sites [205]. Taken together, these data 
demonstrate that interplay between MT1-MMP and FAK is critical for tumor cell 
migration and invasion. 
In this study, we identify Hic-5 as a critical regulator of MT1-MMP and FAK 
during sprouting angiogenesis. Hic-5 was required for successful endothelial sprouting 
responses and lumen formation in 3D matrices. Hic-5 silencing attenuated FAK 
expression and activation as well as MT1-MMP membrane translocation, both events 
known to be indispensable for successful angiogenesis. We show here for the first time a 
complex formed between Hic-5 and MT1-MMP that is enhanced by pro-angiogenic 
sphingolipid, S1P, and requires the LIM2 domain of Hic-5. FAK, Hic-5, and MT1-MMP 
co-localized in 3D endothelial sprouting structures, and levels of Hic-5 and MT1-MMP 
were increased in detergent resistant membrane fractions of invading ECs. Furthermore, 
complex formation between FAK and MT1-MMP was enhanced by nearly four folds in 
presence of Hic-5. Altogether, these data indicate that Hic-5 is required for endothelial 
sprouting and formed a complex with MT1-MMP in response to S1P.  Hic-5 appears to 
act as a scaffold and mediates MT1-MMP and FAK interactions. In conclusion, our data 
provide new evidence about endothelial-specific role for Hic-5 in directing angiogenic 
events.  
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MATERIALS AND METHODS 
Endothelial Cell Culture and Invasion  
Human umbilical vein ECs (HUVECs; Lonza, Allendale, NJ), passages 3-6, and 
were cultured as previously described. 3D invasion experiments were established using 1 
µM S1P (Avanti Polar Lipids, Alabaster, AL) and 40 ng/mL VEGF and bFGF (GF). 
Collagen matrices (2.5 mg/mL) containing S1P were prepared as described previously, 
and invasion responses were quantified for invasion density and distance as previously 
described in detail [45]. 
Hic-5 Cloning 
FLAG-tagged Hic-5 constructs were generated in the pFLAG-CMV2 vector 
(Sigma). HUVEC RNA was isolated using Qiagen’s RNeasy MiniKit as per 
manufacturer’s protocol.   cDNA was generated with Invitrogen’s SuperScript III First-
Strand Synthesis System using 1 ug of RNA.  A PCR reaction was performed using 3µl 
of cDNA template with AccuPrime Taq HIFI Polymerase (Invitrogen), 10 µM of 
forward and reverse primers in a 50 µl reaction volume (Table 1).  The Hic-5 amplicons 
were cleaned with Qiagen’s QIAquick PCR Purification Kit, digested with HindIII 
(NEB) and Xba1 (NEB) as was the pFLAG-CMV2 vector at 37°C overnight, gel 
purified with Qiagen’s QIAquick Gel Extraction Kit, and ligated overnight at 14°C.  For 
deletion constructs, a PCR reaction was performed using FLAG-FL-Hic-5 template with 
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AccuPrime Taq HIFI Polymerase (Invitrogen), 10 µM of forward and reverse primers 
containing a Pac1 (NEB) restriction site in a 50µl reaction volume (Table 1).  PCR 
products were treated with 1 µL Dpn1 (NEB) for 1 h at 37°C, cleaned with Qiagen’s 
QIAquick PCR Purification Kit, digested with Pac1, gel purified using Qiagen’s 
QIAquick Gel Extraction Kit, and ligated overnight at 14°C. Positive clones were 
verified by sequencing before being transfected into 293 cells for binding studies. 
 
 
Table 5. Primer sequences for Hic-5 cloning 
 
 
Construct Primer sets Restr. 
sites 
FLAG-FL-
Hic-5 
5’AGCAAAGCTTGAGGACCTGGATGCCCTG3’ 
5’AGCATCTAGATCAGCCGAAGAGCTTCAGG3’ 
HindIII 
Xba1 
FLAG-N-
Hic-5 
5’AGCAAAGCTTGAGGACCTGGATGCCCTG3’ 
5’AGCATCTAGACCGGCGGCTGAGGTCGGAC3’ 
HindIII 
Xba1 
FLAG-C-
Hic-5 
5’AGCAAAGCTTGGTGTTCCCACCCAGGCC3’ 
5’AGCATCTAGATCAGCCGAAGAGCTTCAGG3’ 
HindIII 
Xba1 
FLAG-
LIM1-2-3 
5’AGCAAAGCTTGAGGACCTGGATGCCCTG3’ 
5’AGCATCTAGATCAGTGGAAGTGGTTCTCGCAC3’ 
HindIII 
Xba1 
FLAG-
LIM1-2 
5’AGCAAAGCTTGAGGACCTGGATGCCCTG3’ 
5’AGCATCTAGATCAGAAGTCCCGGCGGCAGTAG3’ 
HindIII 
Xba1 
FLAG-
LIM1 
5’AGCAAAGCTTGAGGACCTGGATGCCCTG3’ 
5’AGCATCTAGATCAAAAGTAGCACTCGGGGCAG3’ 
HindIII 
Xba1 
FLAG-
∆LIM2 
5’CGCTTCTCGCCAAGATTAATTAAGTGTGGCTTCT
GCAAC3’ 
5’GGCGAACAGCTGCAGTTAATTAAGAAGTCCCGG
CGGCAG3’ 
Pac1 
FLAG-
∆LIM3 
5’CTGTTCGCCCCGCGCTTAATTAAGTGCCAGGGCT
GCCAG3’ 
5’CGAGCCGCGTCGTGCTTAATTAAGTGGAAGTGG
TTCTC3’ 
 
Pac1 
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293 Cell Culture and Transfection 
293 cells (Invitrogen), passages 3-12, were cultured in DMEM and 10% FBS. 
Transfection experiments were established by transfecting 0.4 µg of of each plasmid into 
1x106 cells using Lipofectamine 2000 (Invitrogen) in 6-well plates. Cells were cultured 
for 18 h prior to making extracts for immunoprecipitation experiments. 
Generation of Stable Cell Lines using shRNA 
Lentiviral vectors specific for Hic-5 (#SHCLNG-NM015927) and β2M 
(#SHCLNG-NM004048) were purchased from Sigma-Aldrich. Lentiviral particles were 
generated by transfecting 1.25 μg of backbone shRNA lentiviral plasmid with 3.75 μg of 
VIRAPOWER packaging mix (Invitrogen) into confluent 293 cells (Invitrogen) using 
Lipofectamine 2000 (Invitrogen) in T25 flasks. Viral supernatants were harvested at 60 
h, centrifuged at 1000xg for 10 minutes and filtered through a 0.45 μm filter (Millipore, 
Rockland, MA). 25-30% confluent T25 flasks of HUVECs were infected with 2 mL 
viral supernatant, 3 mL endothelial growth medium, and polybrene (12 μg/mL; Sigma) 
for 5 h. HUVECs were cultured for four days prior to use in experiments. 
Immunoblotting    
Collagen matrices were solubilized in boiling 1.5X Laemmli sample buffer at 
95°C for 5 min to prepare cell lysates. Protein samples were resolved using 8.5-14% 
SDS-PAGE, transferred onto Immobilon PVDF membranes (Millipore), blocked with 
5% nonfat dry milk or 5% BSA, washed, and probed with primary antibodies overnight 
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at 4°C. Membranes were incubated with HRP conjugated secondary antibodies, washed, 
and developed with Immobilon Western Chemiluminescent HRP Substrate (Millipore) 
and HyBlot CL autoradiography film (Denville Scientific, South Plainfield, NJ). The 
antibodies used were directed to: Hic-5 (611164, BD Transduction Laboratories), MT1-
MMP (MAB3328, Millipore), pFAK (ab4803, Abcam), FAK (05-537, Millipore), β2M 
(M8523, Sigma), actin (CP01, Calbiochem), α-tubulin (T6199, Sigma), GAPDH 
(ab8245, Abcam), GFP [64], Flag (ab18230, Abcam), integrin β1 (610467, BD 
Transduction Laboratories), integrin αV (611012, BD Transduction Laboratories), 
vinculin (V9131, Sigma), PECAM-1 (sc1505), and VE-cadherin (sc52751, Santa Cruz). 
Immunoprecipitation 
ECs (3x106 cells) cultured in T75 flasks were serum starved for 4 h and treated 
with 1 µM S1P for 30 min. Cells were placed on ice, washed twice with 10 mL cold PBS 
with cations (0.9 mM Mg2+ and Ca2+), lysed in 700 µL cold lysis buffer (0.5% NP40 in 
PBS with cations, 1X protease inhibitor cocktail (Roche Diagnostics) and 100X HALT 
phosphatase inhibitor), and incubated for 10 min on ice with occasional mixing. Lysates 
were centrifuged at 16,000xg for 15 minutes at 4°C. Supernatants were collected and 
incubated with protein G-magnetic beads (5 µL) for 1 h at 4°C with agitation for 
preclearing. Supernatants were incubated with 2 µg antisera directed to MT1-MMP 
(ab38971, Abcam) or species- specific IgG control for 18 h at 4°C with agitation. Protein 
G-magnetic beads (10 µL) were added for 2 h at 4°C. Beads were washed 5 times with 1 
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mL lysis buffer without protease inhibitors, eluted in 1% SDS and analyzed by Western 
blotting. For IPs with 293 cells, 1x106 cells, cultured in a 6 well plate, were washed 
twice with 1 mL cold PBS with cations, lysed in 700 mL cold lysis buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 1X protease 
inhibitor cocktail (Roche Diagnostics) and 100X HALT phosphatase inhibitor), and 
incubated on ice for 20 min with mixing every 5 min. To test if Hic-5 enhanced MT1-
MMP complex formation with FAK, pre-cleared 293 cell lysates co-transfected with 
MT1-MMP and FLAG-tagged Hic-5 constructs or GFP were allowed to mix with equal 
amounts of pre-cleared 293 cell lysate co-transfected with constitutively active FAK 
(CD2FAK, Addgene) for 2 h at 4°C with gentle agitation. Mixtures were incubated with 
2 µg antisera directed to FAK (ab40794, Abcam) or species-specific IgG control for 18 h at 
4°C with agitation. The remaining steps were performed as described above. 
Immunofluorescence  
ECs were seeded on collagen coated coverslips (50 µg/mL) and allowed to grow 
overnight. Cells were serum starved for 2 h, wounded with a pipette tip and washed 
twice with M199. Cells were treated for times indicated with 1 µM S1P or 40 ng/mL 
growth factors (or both), fixed in 4% paraformaldehyde, and rinsed three times in Tris-
Glycine buffer (0.3% Tris, 1.5% Glycine), and permeabilized with 0.5% Triton X-100 
(TX-100) for 20 minutes with gentle agitation before being blocked in buffer containing 
0.5% TX-100, 1% BSA, and 1% serum overnight at 4°C. Primary antibodies were added 
in blocking buffer (1:100) for 3 h at room temperature, washed, and incubated with 
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Alexa-488- or 594-conjugated secondary antibodies (Molecular Probes, Grand Island, 
NY) (1:300) in blocking buffer for 1 h. After washing, coverslips were mounted and 
imaged using a Nikon TI A1R inverted confocal microscope. Primary antibodies used 
for staining were directed to Hic-5 (611164, BD Transduction Laboratories), pFAK 
(Tyr397, ab4803, Abcam), and VE-cadherin (sc9989, Santa Cruz). Antibodies 
recognizing phosphorylated MT1-MMP (Y397) and pre-immune serum were obtained 
from 21st Century Biochemicals, as previously described [54].  
Isolation of Detergent Resistant Membrane (DRM) Fraction from ECs 
ECs supplemented with 0 or 40 ng/mL GFs were seeded at a density of 30,000 
cells/well on 2.5 mg/mL collagen matrices containing 0 or 1 µM S1P. At 6 h of invasion, 
collagen matrices were washed three times with 200 µL cold PBS with cations. Starting 
material was collected by solubilizing collagen matrices from each treatment group into 
boiling 1.5X sample buffer (50 µL/gel). 100 µL of CSK buffer (10 mM HEPES, 250 
mM sucrose, 150 mM KCl, 3 mM MgCl2, 1 mM EGTA, 1X protease inhibitor cocktail, 
100X HALT phosphatase inhibitor) containing 0.05%, 0.1% or 0.5% TX-100 was added 
consecutively to each collagen matrix and allowed to incubate on ice for 10 min with 
continuous, gentle agitation. Soluble fractions were collected after each CSK wash, and 
after the last wash with 0.5% TX-100 CSK buffer, detergent resistant membrane 
fractions were collected by placing remaining material in 1.5X boiling sample buffer (30 
µL/gel). Starting material, detergent soluble fractions, and detergent resistant membrane 
fractions were analyzed by Western blotting. 
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Isolation of Membrane Fraction from ECs by Subcellular Fractionation 
On day four of lentiviral transfection, shβ2M and shHic-5 ECs cultured in 10 cm 
dishes were serum starved for 2 h prior to treatment with 0 or 1 µM S1P for 1 h. Cells 
were collected in 1.5 mL homogenization buffer (20 mM HEPES (pH 7.4), 1 mM 
EDTA, 250 mM sucrose, 20 mM NaCl, 1.5 mM MgCl2, protease inhibitor cocktail 
(Roche), phenylmethylsulfonyl fluoride (2 mM), 1 mmol/L mercaptoethanol). Cells 
were disrupted by 10 strokes through a 25 gauge needle and homogenates were 
centrifuged at 1000xg for 5 min at 4°C to remove unbroken cells. Protein content of 
supernatants was determined by BCA assay (Thermo Scientific) to ensure equal amounts 
of starting material were centrifuged at 150,000xg for 30 min at 4°C. Cytoplasmic 
proteins in the supernatant were removed and membrane pellets were reconstituted in 
600 µL 1.5X boiling sample buffer, and analyzed by western blotting. 
Imaging and Quantification of Invasion Density, Distance, and Lumen Size 
Top and side views of invading ECs were captured using an Olympus CKX41 
microscope equipped with Q color 3 camera. Invasion densities were quantified by 
counting fixed cultures under transmitted light using an eyepiece equipped with a reticle 
displaying a 10x10 ocular grid. For each condition, at least three random fields were 
selected and the number of invading cells per field was counted manually. Data are 
reported as mean numbers of invading cells per field (±SD). Invasion length was 
measured using digital images taken from a side view of cultures at 10X magnification 
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using Image-Pro Analyzer 7.0. Data are reported as average invasion distance in 
micrometers (±SEM). Approximately 100 cells per treatment group were included in 
analyses. For quantification of lumen size, side view images of cultures at 20X 
magnification were analyzed using Image-Pro Analyzer 7.0. Data are reported as 
percentage of lumens formed in invading structures and average lumen diameter in 
micrometers (±SEM). At least 100 structures per treatment group were included in 
analyses.   
Quantification of Hic-5 Positive Aggregates 
The automated fuzzy thresholding algorithm [208, 209] created with MATLAB code 
was applied to 8-bit TIFF-format immunofluorescence image taken with confocal 
microscopy. This MATLAB algorithm consisted of steps for increasing dynamic range 
with intensity transformation, smoothing images with fuzzy transformation and was able 
to create binary image co-registered with focal adhesion based on histograms of 
smoothed images. The binary image highlighted with focal adhesion locations was 
further used to quantify number or size of focal adhesion per image. 
RESULTS 
Hic-5 was Required for S1P- and GF- Mediated Sprouting 
Recombinant lentiviruses from two individual shRNA sequences targeted against 
Hic-5 (shHic-5-1 and -2) and and shRNA sequence specific to β2-microglobulin 
(shβ2M) were utilized to transduce ECs. To test the effect of Hic-5 depletion on S1P- 
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and GF- mediated invasion, non-transduced ECs (WT), or ECs transduced with 
recombinant lentiviruses directed against β2-microglobulin (shβ2M) or Hic-5 (shHic-5-1 
and -2) were utilized in invasion experiments. Photographs of invading cultures 
illustrated that knockdown of Hic-5 interfered with EC invasion responses stimulated by 
S1P+GF (Fig. 15A). Western blot analyses of extracts collected from invading cultures 
showed selective knockdown of Hic-5 and β2M proteins by their respective shRNAs 
(Fig. 15B). Quantification of invasion density revealed a significantly decreased number 
of invading cells with Hic-5 silencing compared to shβ2M controls (Fig. 15C). In 
addition, the length of invading structures was significantly decreased with Hic-5 
silencing compared to shβ2M controls (Fig. 15D). These results demonstrated that Hic-5 
was required for S1P- and GF- stimulated EC invasion in 3D collagen matrices. 
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Figure 15. Hic-5 was required for S1P- and GF- mediated EC invasion. (A) 
Non-transduced ECs (WT), or ECs transduced with lentiviruses delivering 
shRNA directed to β2-microglobulin (shβ2M-1 and -2) or Hic-5 (shHic-5-1, and -
2) were tested in 3D invasion assays using S1P+GF. Invasion cultures were fixed 
at 20h with 3% glutaraldehyde, stained with toluidine blue and photographed to 
illustrate side view of invasion responses. Scale bar=50 μm. (B) Cell lysates from 
treatment groups as in (A) were analyzed by Western blotting using Hic-5-, β2M-, 
GAPDH-, actin-, and tubulin-specific antisera to verify β2M and Hic-5 protein 
suppression. Quantification of (C) invasion density and (D) invasion distance at 
20 h of invasion. Data in (C) represent average number of invading cells per 1 
mm2 field ± SD (n=3 fields, Students t-test, ***p<0.001, **p<0.01, compared to 
shβ2M). Data in (D) represent average length of structures ±SEM (n>100 cells; 
Students t-test, ***p<0.001 compared to shβ2M). Representative experiment 
shown (n=4). 
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S1P Promoted Hic-5 Colocalization with FAK 
Hic-5 silencing interfered with endothelial invasion responses that were 
stimulated by S1P and GFs. To determine the effect of either S1P or GF on Hic-5 
localization, ECs seeded onto collagen-coated coverslips were serum starved and not 
treated (control) or treated with 1 µM S1P or 40 ng/mL GF (VEGF + bFGF) or both and 
stained with Hic-5 specific antisera. We observed that S1P treatment increased Hic-5 
positive aggregates at the cell periphery (Fig. 16A). Quantification of size of Hic-5 
positive structures revealed that S1P and S1P+GF treatment had significantly larger Hic-
5 positive aggregates (Fig. 16B). To determine if S1P upregulated Hic-5 expression, 
whole cell lysates from ECs serum starved for 2 h were treated with 1 µM S1P for 0, 15, 
30, or 60 min. Western blot analyses revealed that S1P treatment did not increase total 
levels of Hic-5 (Fig. 16C), demonstrating that S1P mediated a translocation but not 
upregulation of Hic-5. Since Hic-5 is described as a focal adhesion scaffold protein, and 
S1P is known to mediate translocation of focal proteins to adhesion sites, we further 
investigated if Hic-5 positive aggregates were focal adhesions.  ECs seeded on collagen 
coated coverslips were serum starved, treated with S1P for the indicated times, and 
stained with Hic-5- and pFAK (Y397)-specific antisera (Fig. 17). Hic-5 (red) and pFAK 
(green) overlap indicated that S1P mediated Hic-5 translocation to focal adhesion sites. 
Taken together, these data suggested that Hic-5 localized to focal adhesion sites in 
response to S1P treatment.  
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Figure 16. S1P altered Hic-5 localization in ECs. (A) ECs seeded on collagen 
(50 µg/mL) coated coverslips were serum starved for 2h and left untreated (CON) 
or treated with 1 µM S1P (S1P), or 40 ng/mL VEGF and bFGF (GF) or both 
(S1P+GF) for 1h. Following paraformaldehyde fixation, cells were stained with 
anti-Hic-5 detected with species-specific secondary antibodies conjugated to 
Alexa Fluor 594. Images were collected using Nikon A1 confocal laser 
microscopy. Scale bar=10 μm. (B) Quantification of average size (in microns) of 
Hic-5 positive aggregates as observed in (A) using MATLAB code created to 
quantify focal adhesion size. Data are representative of three independent 
experiments.  (Students t-test, ***p<0.001, as compared to CON). (C) ECs 
seeded in 12-well plates were serum starved for 2h and treated with 1 µM S1P for 
indicated time prior to making whole cell lysates. Western blot analyses of cell 
lysates were performed using Hic-5-, actin-, GAPDH-, and tubulin- specific 
antisera. 
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Figure 17. S1P promoted Hic-5 co-localization with pFAK. ECs seeded 
overnight on collagen coated coverslips were serum starved for 2h and treated 
with 1 µM S1P for indicated times. Cells were fixed in 4% paraformaldehyde, 
stained with anti-Hic-5 and anti-pFAK antibodies and detected with species-
specific secondary antibodies conjugated to Alexa Fluor 488 and Alexa Fluor 594, 
respectively. Images were collected using confocal microscopy. Scale bar=10 μm. 
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Hic-5 Depletion Resulted in Attenuated FAK Expression and Activation 
We and others have shown that FAK activation and expression is crucial for 
successful endothelial sprouting [139, 142, 210]. Recent studies in breast cancer cells 
demonstrate a requirement for Hic-5 during robust focal adhesion formation in 3D cell-
derived matrix (CDM) [211]. To determine if Hic-5 regulated expression or activation of 
FAK in S1P- and GF-stimulated endothelial invasion, ECs transduced with recombinant 
lentiviruses expressing short hairpin RNAs directed against Hic-5 (shHic-5) or β2M 
(shβ2M) were allowed to invade collagen matrices. Whole cell extracts collected from 
invading cultures at 0, 0.5, and 1 h were analyzed by Western blotting. We observed a 
decrease in total and phosphorylated (Y397) FAK levels with Hic-5 knockdown 
compared to shβ2M controls (Fig. 18A). Quantification of Western blots revealed a 
significant decrease in the expression of phosphorylated (Y397) and total FAK at all 
time-points in shHic-5 versus shβ2M expressing ECs (Fig. 18B and 18C). These data 
suggested that Hic-5 was required for FAK expression and activation to direct successful 
endothelial sprouting. 
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Figure 18. Hic-5 depletion decreased levels of pFAK and total FAK. (A) ECs 
were transduced with shRNA directed to β2M (shβ2M) and Hic-5 (shHic-5) and 
placed in invasion assays in the presence of S1P+GF. Whole cell lysates were 
prepared at the indicated time points. Western blot analyses were conducted using 
polyclonal antisera directed to phospho-FAK (Y397) and β2M, as well as 
monoclonal antisera directed to total FAK, tubulin, and Hic-5. (B) Quantification 
of FAK protein expression was performed using Image J software and normalized 
to tubulin. The results represent average values ± SD in arbitrary units (a.u.) from 
three independent experiments (Students t-test, ***p<0.001, * p<0.05, compared 
with shβ2M). (C) Quantification of pFAK protein expression using Image J 
software and normalized to tubulin. The results represent average values ± SD in 
arbitrary units (a.u.) from three independent experiments (Students t-test, 
**p<0.01, * p<0.05, as compared with shβ2M). 
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Hic-5 was Required for Successful Lumen Formation during Endothelial Sprouting 
To test the effect of Hic-5 depletion on endothelial lumen formation, non-
transduced or ECs transduced with recombinant lentiviruses directed against β2-
microglobulin (shβ2M) or shHic-5-1 and -2 were utilized in S1P- and GF-mediated 
sprouting assay. Side view photographs of invading cultures illustrated that knockdown 
of Hic-5 resulted in smaller lumens compared to WT or shβ2M controls (Fig. 19A). 
Quantification of lumen size from three independent experiments revealed a significant 
decrease in lumen diameter with Hic-5 knockdown (Fig. 19B). Also, the number of 
invading cells forming lumens was lesser with Hic-5 silencing compared to WT and 
shβ2M controls (Fig. 19C). These results demonstrated that Hic-5 was required for 
successful lumen formation during endothelial morphogenesis in 3D collagen matrices. 
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Figure 19. Hic-5 was required for successful lumen formation during 
endothelial sprouting. (A) Representative photographs of a side view of invading 
structures from non-transduced ECs (HUVEC) or ECs transduced with lentiviruses 
delivering shRNA directed to β2M (shβ2M) or Hic-5 (shHic-5-1, and -2). Black 
arrows indicate lumens. Quantification of (B) average lumen diameter (in microns) 
and (C) percentage of cells forming lumens from invading cultures in (A) (n>100 
cells). Results are representative of three independent experiments. (Students t-test, 
***p<0.001, as compared with shβ2M).      
 
 
  
Hic-5 Complexed with MT1-MMP in an S1P- Dependent Manner in ECs 
Endothelial lumenogenesis is a critical step needed for successful morphogenesis 
and assembly of ECs into new vessels [43]. Several studies have demonstrated that 
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proper MT1-MMP signaling is required for successful lumen formation during 
angiogenesis [26, 212, 213]. Our data suggested that Hic-5 silencing interfered with 
lumen formation during S1P- and GF-dependent sprouting responses. Moreover, both 
MT1-MMP [214, 215] and Hic-5 [185] are known to be enriched in invadopodia of 
migrating cells. Also, MT1-MMP is recruited to focal adhesion sites and regulated FA-
type matrix degradation in tumor cells [205]. Therefore, we next asked whether Hic-5 
co-localized with MT1-MMP in ECs. ECs seeded on collagen coated coverslips were 
serum starved for 2h, treated with nothing (CON), 1 µM S1P (S1P), 40 ng/mL GF (GF) 
or S1P and GF (S1P+GF) for 1h and stained with Hic-5 (red) or pMT1-MMP (Y573, 
green). Overlay photographs indicated successful colocalization between Hic-5 and 
pMT1-MMP in ECs treated with S1P or S1P+GF (Fig 20). These data suggested 
enhanced interactions between Hic-5 and MT1-MMP may occur with S1P treatment. To 
confirm this, ECs were treated with 0 or 1 µM S1P for 30 min, and lysates were 
immunoprecipitated using MT1-MMP- or species-specific IgG antisera. While equal 
amounts of MT1-MMP were immunoprecipitated in both treatment groups (Fig 21A), 
we observed an increase in complex formation between Hic-5 and MT1-MMP with S1P 
stimulation. Quantification of western blots from three independent experiments 
revealed that S1P treatment significantly increased Hic-5 and MT1-MMP complex 
formation (Fig 21B). Taken together, these data revealed a novel complex formation 
between focal adhesion scaffold protein Hic-5 and MT1-MMP formed following S1P 
stimulation in ECs. 
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Figure 20. Hic-5 co-localized with activated MT1-MMP in an S1P- dependent 
manner. ECs seeded on collagen coated coverslips were serum starved for 2h and 
left untreated (CON) or treated with 1 µM S1P (S1P), or 40 ng/mL VEGF and 
bFGF (GF) or both (S1P+GF) for 1h. Cells were fixed in 4% paraformaldehyde, 
stained with anti-Hic-5 and anti-pMT1-MMP and detected with species-specific 
secondary antibodies. Images were collected using confocal microscopy. Scale 
bar=10 μm. 
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Figure 21. Hic-5 complexed with MT1-MMP in an S1P- dependent manner. 
(A) ECs cultured in T75 flasks for 3 days were stimulated with nothing (CON) or 
1 μM S1P (S1P) for 1 h. Immunoprecipitations were performed using polyclonal 
MT1-MMP antibody or isotype control (IgG). Eluates were probed with MT1-
MMP- and Hic-5- specific antisera using Western blotting. (B) Quantification of 
co-precipitated Hic-5 normalized to starting material from Western blots using 
Image J software. The results represent average values ± SD in arbitrary units 
(a.u.) from three independent experiments (Student’s t-test, **p<0.01, compared 
to CON). 
 
 
 
LIM2 Domain of Hic-5 was Required for Binding to MT1-MMP 
Based on the above data that Hic-5 complexed with MT1-MMP in ECs, we next 
determined MT1-MMP binding site on Hic-5 with various Hic-5 mutant proteins 
outlined in Table 6. Initially, full-length (FL) His-tagged MT1-MMP was co-transfected 
with FL FLAG-tagged Hic-5, N-terminal FLAG-tagged Hic-5, C-terminal FLAG-tagged 
Hic-5, or GFP in 293 cells (Fig. 22A). Immunoprecipitation experiments were 
performed by incubating lysates with MT1-MMP- or species-specific IgG antisera. 
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Western blot analyses revealed successful expression of MT1-MMP, GFP, and Hic-5 
constructs in the starting material. Moreover, we observed successful MT1-MMP 
complex formation with FL Hic-5 and C-terminal Hic-5 constructs, but not with N-
terminal Hic-5 (Fig. 22A). These data suggested that one or more LIM domains at the C-
terminus of Hic-5 may be involved in MT1-MMP binding.  To identify the specific 
domain(s) involved in MT1-MMP binding, additional FLAG-tagged truncation and 
deletion constructs of Hic-5 were generated (see Table 6). FL His-tagged MT1-MMP 
was co-transfected with FL Hic-5, LIM1-2-3, LIM1-2, LIM1, ∆LIM2, or ∆LIM3 in 293 
cells (Fig. 22B). Western blot analyses revealed no complex formation with LIM1 or 
∆LIM2 constructs and MT1-MMP. However, successful MT1-MMP association was 
observed with FL Hic-5, LIM1-2-3, LIM1-2, and ∆LIM3 constructs (Fig. 22B). These 
data indicated that the LIM2 domain within the C-terminus of Hic-5 was essential for 
MT1-MMP binding.    
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Table 6. Summary of MT1-MMP and Hic-5 binding studies 
 
FLAG-Hic-5 constructs 
Binding to His-MT1-
MMP 
FL Hic-
5 
 
+++ 
N-Hic-5 
 
- 
C-Hic-5 
 
+++ 
LIM1-2-
3  
 
+++ 
LIM1-2 
 
 
+ 
LIM1 
 
 
- 
∆LIM2 
 
 
- 
∆LIM3 
 
 
+ 
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Figure 22. The LIM2 domain of Hic-5 was required for MT1-MMP binding.  
(A) 293 cells were co-transfected with His-MT1-MMP and GFP or FLAG-tagged 
FL-Hic-5 (full-length), N-Hic-5 (N-terminal) or C-Hic-5 (C-terminal) constructs. 
Immunoprecipitation experiments were performed using polyclonal MT1-MMP 
antibody or isotype control (IgG). Eluates were probed with MT1-MMP-, GFP- 
and FLAG- specific antisera using Western blotting. (B) 293 cells were co-
transfected with His-MT1-MMP and FLAG-tagged FL-Hic-5 (full-length), LIM1-
2-3, LIM1-2, LIM1, ∆LIM2, and ∆LIM3 constructs. Immunoprecipitation 
experiments were performed using polyclonal MT1-MMP antibody or isotype 
control (IgG). Eluates were probed with MT1-MMP- and FLAG- specific antisera 
using Western blotting. 
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Figure 22. Continued  
 
 
 
 
MT1-MMP and Hic-5 Were More Resistant to Detergent Extraction during 
Endothelial Invasion 
To determine whether MT1-MMP, Hic-5, and FAK complex assembly was 
altered in non-invading versus invading cells, invading cultures were not treated (CON) 
or stimulated with 1 µM S1P and 40 ng/mL GFs (S1P+GF), respectively. Extracts were 
made at 6 h by washing collagen matrices with increasing concentrations of TX-100 
(0.05%, 0.1% and 0.5%) and remaining material was collected, solubilized, and 
designated as detergent resistant membrane (DRM) extracts. In agreement with previous 
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reports [216, 217], we observed successful upregulation of MT1-MMP in DRM extracts 
in invading ECs stimulated with S1P and GF (Fig. 23A), and we also observed an 
increase in the levels of Hic-5 in DRM extracts collected from sprouting ECs that 
followed the MT1-MMP pattern. Interestingly, FAK levels in DRM extracts were not 
significantly elevated by S1P and GF treatment. The β1 integrin and αV integrin 
subunits were also upregulated in DRM fractions of invading ECs, while levels of 
vinculin and actin and remained unchanged. GAPDH was not detected in DRMs 
supporting successful isolation of DRM fractions (Fig. 23A). Quantification of MT1-
MMP, FAK, and Hic-5 levels in DRMs from three independent experiments revealed a 
significant increase of MT1-MMP and Hic-5 levels, but not FAK, in DRM extracts in 
invading versus non-invading cells (Fig. 23B). Overall, these data indicate that the MT1-
MMP and Hic-5 complex is more resistant to detergent extraction in invading cells 
suggesting the formation of this complex within the membrane facilitates EC sprouting 
responses in 3D collagen matrices. 
 
 
  
92 
 
 
 
Figure 23. Hic-5 and MT1-MMP were more resistant to detergent extraction 
during endothelial invasion. (A) Detergent resistant membrane (DRM) extracts 
were isolated from invasion cultures without (CON) or with (S1P+GF) 1 µM S1P 
and 40 ng/mL GFs. Starting material lysates, soluble lysates (obtained with 0.05% 
and 0.1% TX-100 treatment)  and DRM extracts and were analyzed by western 
blotting and probed with FAK-, MT1-MMP-, Hic-5-, vinculin-, integrin β1-, 
integrin αV-, actin-, and GAPDH- specific antisera. Quantification of (B) MT1-
MMP, Hic-5, and FAK levels in DRM normalized to starting material from 
Western blots using Image J software. The results represent average values ± SD 
in arbitrary units (a.u.) from three independent experiments (Student’s t-test, 
*p<0.05, compared to CON). 
 
 
 
 
Hic-5 Silencing Interfered with MT1-MMP Membrane Translocation 
The data shown above demonstrate Hic-5 was required for sprouting and formed 
a complex with MT1-MMP that was enhanced by S1P and more resistant to detergent 
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extraction. S1P has been shown to stimulate MT1-MMP membrane translocation during 
angiogenesis [66, 218]. To test whether Hic-5 was needed for membrane localization of 
activated MT1-MMP, ECs expressing shRNA directed to β2M (shβ2M) and Hic-5 
(shHic-5) were seeded on collagen coated coverslips, serum starved, and treated with 
S1P. Coverslips were stained with VE-cadherin- and pMT1-MMP (Y573)-specific 
antisera. We observed successful membrane translocation of pMT1-MMP in shβ2M 
control at 60 min of S1P stimulation. However, Hic-5 silencing reduced co-localization 
of MT1-MMP with VE-Cadherin (Fig. 24A and 24B). Endothelial junctions visualized 
by VE-cadherin staining were unaffected with Hic-5 knockdown. Quantification of 
colocalization between VE-cadherin and pMT1-MMP revealed a significant decrease in 
overlap with Hic-5 silencing at 60 min of S1P stimulation (Fig. 24C).  To confirm these 
observations, membrane fractions were isolated from shβ2M and shHic-5 cells treated 
with 0 or 60 min of S1P. Analysis of membrane extracts by western blotting revealed an 
upregulation of MT1-MMP levels in shβ2M control with S1P treatment but not in the 
shHic-5 group (Fig. 12A). As observed previously (Fig. 18), FAK levels were reduced 
with Hic-5 silencing. Also, cytoplasmic proteins like actin, tubulin, and GAPDH were 
not detected in membrane fractions, but PECAM-1 and VE-Cadherin were present, 
supporting successful membrane isolation (Fig. 25A). Quantification of MT1-MMP 
levels in membrane fractions from three independent experiments with 60 min S1P 
treatment revealed a significant decrease in MT1-MMP levels with Hic-5 depletion (Fig. 
25B). Taken together, these studies suggest that Hic-5 may facilitate MT1-MMP 
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translocation to the cell surface where MT1-MMP is needed for successful sprouting 
responses in ECs.  
 
 
 
Figure 24. Hic-5 silencing attenuated pMT1-MMP membrane translocation. 
(A) ECs transduced with shRNA directed to β2M (shβ2M) or Hic-5 (shHic-5)   
were seeded on collagen coated coverslips, serum starved for 2h and treated with 
1 µM S1P for the indicated times. After paraformaldehyde fixation, shβ2M and 
shHic-5 cells were stained with anti-Hic-5 and anti-pMT1-MMP antibodies and 
detected with species-specific secondary antibodies conjugated to Alexa Fluor 
488 and Alexa Fluor 594. Images were collected using confocal microscopy. 
Scale bar=10 μm. (B) 2X magnified images at 60min S1P treatment in shβ2M and 
shHic-5 groups from (A). (C) Quantification of Hic-5 (green) and VE-cadherin 
(red) co-localization using Pearson’s correlation coefficient. The results represent 
average values ± SD from each treatment group (n>10 fields) for a representative 
experiment (n=4) (Student’s t-test, ***p<0.001, compared to shβ2M).   
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Figure 24. Continued  
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Figure 25. Hic-5 depletion resulted in decreased levels of MT1-MMP at the 
endothelial membrane following S1P treatment. (A) Membrane fractions were 
isolated from ECs transduced with shRNA directed to β2M (shβ2M) or Hic-5 
(shHic-5), serum starved for 2h and treated with 0 or 1µM S1P for 1h. Membrane 
fractions and starting materials were analyzed by western blotting and probed 
with MT1-MMP-, Hic-5-, FAK-, vinculin-, PECAM-1-, VE-cadherin-, tubulin-, 
actin-, and GAPDH- specific antisera. (B) Quantification of MT1-MMP in 
membrane fraction normalized to starting material from Western blots using 
Image J software. The results represent average values ± SD in arbitrary units 
(a.u.) from three independent experiments (Student’s t-test, **p<0.01, compared 
to shβ2M). 
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Hic-5 Enhanced Complex Formation Between FAK and MT1-MMP  
McNiven and colleagues have reported that that complex formation between 
FAK and MT1-MMP is crucial for matrix degradation at focal adhesion sites [205]. Like 
other paxillin family members, Hic-5 mediates multiple protein-protein interactions at 
adhesion sites via its LD and LIM domains [219, 220]. Our data clearly suggests a 
complex forms between MT1-MMP and Hic-5 in ECs. Also, MT1-MMP and Hic-5 
levels increased in DRMs of invading ECs. Therefore, we further investigated whether 
Hic-5 mediated MT1-MMP and FAK binding. To address this question, we combined 
cell lysates expressing constitutively active FAK with separate lysates containing FL 
His-tagged MT1-MMP co-transfected GFP, FL FLAG-tagged Hic-5, or ∆LIM2. 
Immunoprecipitations were performed with FAK-specific antisera and eluates were 
probed for MT1-MMP, Hic-5, and FAK using Western blot analyses. We observed 
robust complex formation between MT1-MMP and FAK in the presence of FL Hic-5 
compared to GFP or ∆LIM2 (Fig. 26A). Equivalent amounts of FAK were 
immunoprecipitated in all conditions (Fig 26A). Interestingly, we observed a weak 
association of ∆LIM2 and FAK as compared to FL Hic-5 (Fig. 26A), which agreed with 
a previous report which showed that although Hic-5 interacted with FAK via its N-
terminal LD domains, the C-terminal LIM domains were required for targeting Hic-5 to 
focal adhesion sites [174]. Quantification of western blots from three independent 
experiments revealed that the presence of FL Hic-5 significantly increased MT1-MMP 
complex formation with FAK compared to GFP and ∆LIM2 controls (Fig. 26B). In 
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conclusion, these results suggested that Hic-5 enhanced complex formation between 
MT1-MMP and FAK. 
 
 
Figure 26. Hic-5 mediated complex formation between FAK and MT1-MMP. 
(A) 293 cells were co-transfected with His-MT1-MMP and GFP, FL-Hic-5, or 
∆LIM2 constructs in 6 well plates (Lysate 2). Constitutively active FAK 
(CD2FAK) was overexpressed separately in 293 cells (Lysate 1). 700 uL lysates 
were prepared from each well for all treatment groups. Equal amounts of lysate 1 
and lysate 2 were allowed to mix for 2h at 4°C before immunoprecipitating with 1 
µg monoclonal FAK antibody or isotype control (IgG) antibodies. Eluates were 
probed with FAK-, Hic-5- and MT1-MMP- specific antisera using western 
blotting. (B) Quantification of co-precipitated MT1-MMP normalized to starting 
material from Western blots using Image J software. The results represent average 
values ± SD in arbitrary units (a.u.) from three independent experiments 
(Student’s t-test, **p<0.01, compared to MT1+GFP and MT1+∆LIM2 controls). 
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DISCUSSION 
We have investigated and report a new regulatory role of the focal adhesion 
scaffold protein Hic-5 during sprouting angiogenesis in 3D collagen matrices. Our 
results suggested that Hic-5 regulated endothelial sprouting reponses by (i) regulating 
FAK expression and activation, (ii) associating with MT1-MMP, (iii) regulating MT1-
MMP membrane translocation, and (iv) mediating FAK and MT1-MMP interactions. 
Our results are the first to demonstrate a complex formation between Hic-5 and 
MT1-MMP during endothelial sprouting. Hic-5 was discovered as a cDNA clone 
induced by TGFβ stimulation [171]. Further studies described Hic-5 as a focal adhesion 
scaffold protein based on a lack of enzymatic activity, homology to paxillin, localization 
at FA sites, and interaction with FA proteins [220]. Like other LIM proteins, Hic-5 was 
found to translocate into the nucleus and regulate gene expression upon oxidative stress 
[181, 221]. Hic-5 acts as a transcriptional co-activator for glucocorticoid receptor [65, 
66], endogeneous c-Fos [37], specificity protein 1 (Sp1) [38], and Peroxisome 
proliferator-activated receptor γ (PPARγ) [67]. Hic-5 has also been reported to act as 
repressor for lymphoid enhancer-binding factor and transcriptional factor (LEF/TCF) 
driven transcription [68]. Evidence from cancer cells suggests that Hic-5 may be 
important during cell migration [186, 211, 222]. However, the molecular mechanisms 
that define the function of Hic-5 in regulating cell migration and focal adhesion 
assembly are not fully understood. Also, a role for Hic-5 during angiogenesis and 
endothelial sprouting remains unexplored. We show here for the first time a requirement 
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for Hic-5 during endothelial sprouting and lumen formation in 3D matrices. Our data 
demonstrate that S1P stimulation increased Hic-5 complex formation with MT1-MMP 
during EC sprouting. MT1-MMP is a major membrane bound metalloprotease that is 
involved in enzymatic breakdown of surrounding ECM proteins to facilitate cell 
invasion in 3D matrices [191, 192]. Several studies have demonstrated a requirement for 
MT1-MMP in directing successful endothelial sprouting and lumen formation as well as 
cancer cell invasion [193, 196, 223]. Previous work from our laboratory indicated that 
proper membrane translocation of MT1-MMP, occurred when soluble vimentin was 
liberated in activated ECs, facilitating successful endothelial sprout formation [66]. We 
find here that Hic-5 regulated EC invasion through a unique pathway involving MT1-
MMP and FAK. 
FAK is a major focal kinase protein that plays a key role in cell migration and 
endothelial morphogenesis [136, 224]. Numerous studies have reported that FAK is 
essential for embryogenesis, cardiovascular development, EC survival, endothelial 
morphogenesis and angiogenesis [139-142, 198, 199]. In agreement with these data, we 
have previously observed that blocking FAK activation completely inhibited sprouting 
in ECs [210]. Recent studies by Deakin and Turner suggest that Hic-5 depletion in tumor 
cells significantly hampered focal adhesion formation in 3D ECM and decreased FAK 
phosphorylation [211]. In this study, we find that Hic-5 silencing attenuated FAK 
phosphorylation (Y397) and expression in ECs. These results help explain, in part, the 
requirement of Hic-5 for successful endothelial sprouting.  
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S1P is a bioactive sphingolipid that increases EC proliferation, barrier 
enhancement, and stimulates endothelial sprouting [59-62]. Others have reported that 
S1P directed rapid translocation of FA to proteins FA sites [65]. In agreement with these 
data, we observed rapid translocation of Hic-5 to FA sites as well as EC junctions. 
Interestingly, S1P is also known to activate MT1-MMP and mediate its membrane 
translocation [225]. Studies by Pignatelli et al., have demonstrated in tumor cells that 
Hic-5 was required for successful matrix degradation [186]. Our results indicated that 
Hic-5 knockdown interfered with lumen formation in endothelial sprouts, which is MT1-
MMP dependent. Wang and McNiven have reported that FAs are potential sites for 
MT1-MMP dependent invasive matrix degradation [205]. Our immunofluorescence data 
revealed that S1P induced co-localization between these proteins at punctate FA sites at 
the endothelial cell periphery. Immunoprecipitation studies confirmed an up-regulation 
of Hic-5 and MT1-MMP complex formation with S1P stimulation. Moreover, we also 
observed that MT1-MMP and Hic-5 levels were enhanced in DRM fractions of invading 
ECs, indicative of their interplay during endothelial sprouting in response to S1P and 
pro-angiogenic GFs. Our results are the first to report an S1P- dependent complex 
formation between Hic-5 and MT1-MMP in ECs.  
Both LD and LIM domains in Hic-5 participate actively in protein binding [175]. 
To further investigate the MT1-MMP binding domain in Hic-5, we used in vitro binding 
studies. Our results indicated that the LIM2 domain of Hic-5 was required in binding 
with MT1-MMP. Interestingly, we also observed weak MT1-MMP association with 
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LIM3 deletion, suggesting that LIM3 was not required but enhanced MT1-MMP binding 
to Hic-5. LIM3 has been implicated in successful targeting of Hic-5 to FA sites [174] 
and Hic-5 constructs bearing mutations in the LIM3 site (C369A/C372A) fail to localize 
to FAs upon LPA stimulation [185]. Thus, we speculate that successful targeting of Hic-
5 to FAs improves interaction with MT1-MMP. To determine the role of Hic-5 in MT1-
MMP signaling, we looked at levels of MT1-MMP at the endothelial membrane 
following S1P stimulation. Our results indicated that Hic-5 depletion significantly 
attenuated S1P- mediated MT1-MMP membrane translocation. These results suggested 
that Hic-5 acted as a molecular adaptor in transporting MT1-MMP to plasma membrane 
for successful sprouting responses. 
Several reports have implicated the importance of MT1-MMP and FAK crosstalk 
during cell migration [204, 206, 207].  Studies by Wang and McNiven have 
demonstrated that the interaction between MT1-MMP and FAK is essential for 
mediating matrix degradation at FA sites [205]. Their results indicate p130Cas  mediates 
MT1-MMP and FAK interactions [205]. Moreover, S1P is known to stimulate binding 
between MT1-MMP and p130Cas in ECs [218]. Since Hic-5 is a scaffold protein known 
to mediate protein interactions at FAs, we investigated whether Hic-5 regulated MT1-
MMP and FAK interactions. Our data from in vitro binding studies indicated that the 
presence of full-length Hic-5 enhanced MT1-MMP and FAK interactions by more than 
4-fold. These results indicate that Hic-5 acted as a scaffold to enhance interaction 
between MT1-MMP and FAK.  
  
103 
 
 
In summary, our findings reveal novel functions of Hic-5 in mediating 
endothelial sprouting. Following S1P stimulation, Hic-5 is translocated to FAs and 
complexes with MT1-MMP; which is required for optimal interactions between MT1-
MMP [226, 227] and FAK [228, 229] to mediate matrix degradation at FA sites. In 
addition, our results demonstrate that Hic-5 is also required for FAK activation and 
expression as well as MT1-MMP membrane translocation [186, 211]. Several reports 
have implicated a role for MT1-MMP and FAK during tumor progression and invasion 
in 3D ECM. Recent studies have determined a role for Hic-5 in tumor cell attachment, 
matrix degradation, migration and invasion. Our results provide new information on the 
interplay of these molecules and may be relevant in regulating metastatic behavior of 
cancer cells. 
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CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
In conclusion, we have demonstrated that both RACK1 and Hic-5, scaffold 
proteins known to be associated with focal adhesions, are required for S1P- and GF- 
induced sprouting angiogenesis.  RACK1 is up-regulated along with vimentin, in 
sprouting versus quiescent ECs. Moreover, RACK1 and vimentin, both complex 
together in GF- dependent manner and regulate FAK in ECs. Silencing of either RACK1 
or vimentin attenuated cell attachment and disturbed focal adhesion distribution. 
RACK1, vimentin, and FAK formed a complex during endothelial sprout formation in 
3D collagen matrices. RACK1, vimentin and FAK activation were required for 
successful endothelial sprouting. Also RACK1 silencing decreased complex formation 
between vimentin and FAK. These data added new insights into the role of RACK1 
during angiogenesis. 
Like RACK1 and vimentin, we observed that focal adhesion scaffold protein 
Hic-5 also regulated FAK expression and activation. S1P induced Hic-5 translocation at 
adhesion sites in ECs. Moreover, Hic-5 silencing decreased endothelial sprouting and 
lumen formation in S1P- and GF- mediated angiogenesis. Interestingly, S1P induced 
complex formation between Hic-5 and MT1-MMP, a surface metalloproteinase known 
to drive ECM degradation at focal adhesion sites as well as invadopodia [205]. We 
identified the MT1-MMP binding domain on Hic-5 to be LIM2. Also, our results 
indicated that Hic-5 regulated MT1-MMP membrane translocation. Hic-5 and MT1-
  
105 
 
 
MMP were enriched in detergent resistant lipid rafts of invading ECs. Association 
between MT1-MMP and FAK was increased over three folds in presence of Hic-5, 
suggesting that Hic-5 adapted MT1-MMP to FAK. These evidences uncover novel 
functions of Hic-5 during endothelial invasion and lumen formation. Taken together, 
these studies shed light on the roles of RACK1 and Hic-5 during angiogenesis (Fig. 27).  
Several studies have demonstrated that MT1-MMP, FAK [164, 165], RACK1 
[128, 166, 167], and vimentin [168, 169] are up-regulated during tumor formation, 
invasion and metastasis. Moreover, recent studies have implicated a requirement of Hic-
5 during breast cancer cell migration and invasion in 3D ECM [186, 211]. Since 
expression of all these molecules is altered during malignant disease, these pathways 
may regulate invasive, metastatic cell behavior. Our data provide novel insights into the 
role of RACK1 and Hic-5 during endothelial invasion in 3D collagen matrices. 
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Figure 27. Roles of scaffold proteins RACK1 and Hic-5 during endothelial 
sprouting 
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FUTURE DIRECTIONS 
In this study, we have elucidated two pathways that contribute towards 
successful endothelial sprouting responses in 3D collagen matrices. Our results are 
stepping stones towards a number of potential investigations. One interesting possibility 
would be to explore cross talk between RACK1 and Hic-5 pathways. Several lines of 
evidence suggest common characteristics between RACK1 and Hic-5. Both of these 
proteins are molecular scaffolds that lack enzymatic activity and majorly function as 
mediators of protein-protein interactions. RACK1 structure has characteristic WD repeat 
motif [127] while Hic-5 has LD and LIM domains to enable multiple protein interactions 
[176, 221]. Both Hic-5 [174] and RACK1 [230] are localized at focal adhesions and are 
known to interact with FAK. RACK1 is required for achieving optimal FAK activation 
following ECM engagement [122, 126] while Hic-5 silencing attenuates FAK expression 
as well as activation. Our results indicate that RACK1 and Hic-5 are required for 
successful sprouting responses in ECs.  Moreover, their expression profiles or 
localization is altered with pro-angiogenic stimuli. RACK1 is up-regulated during S1P- 
and GF- induced angiogenesis while Hic-5 is localized to focal adhesion sites with S1P 
treatment. Our data revealed that RACK1 and Hic-5 complexed with important 
regulators of angiogenesis in ECs. Pro-angiogenic GFs induced complex formation 
between RACK1 and vimentin, while Hic-5 complexed with MT1-MMP in S1P- 
dependent manner. Interestingly, previous studies from our laboratory have revealed that 
soluble vimentin filaments transport MT1-MMP to endothelial surface in response to 
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pro-angiogenic stimuli to direct matrix degradation and sprouting [66]. Keeping in mind 
this evidence, an intriguing possibility would be to determine if Hic-5 and/or RACK1 is 
transported along with MT1-MMP to focal adhesion sites via vimentin filaments. In 
support of this theory, we find that Hic-5 is required for successful membrane 
translocation of MT1-MMP. Whether RACK1 affects MT1-MMP regulation is ECs 
remains to be determined. Since calpains are known to cleave vimentin, it would be 
interesting to test if calpains are involved upstream of this pathway.  
Another potential area of investigation would be to probe for the phosphorylation 
states of RACK1 and Hic-5 in invading endothelial cells. RACK1 structure consists of 
six tyrosine residues that are known to be phosphorylated to mediate varied RACK1 
functions. Insulin like growth factor 1 (IGF-1) mediated phosphorylation of RACK1 at 
Y52 by c-Abl mediates its interaction with FAK at focal adhesion sites [122]. This 
interaction between RACK1 and FAK is important to mediate adhesion signaling 
downstream of ECM engagement and integrin ligation [122]. Interestingly, c-Abl is 
known to participate in endothelial barrier enhancement, downstream of S1P signaling 
[163, 231-233]. Y302 phosphorylation on RACK1 directs its association with protein 
phosphatase 2A (PP2A) and integrin β1 which is important for regulation of PP2A 
activity and IGF-1 induced cell migration [144, 146]. Thus, RACK1 phosphorylation 
seems to correlate with cell migration. Src kinase is also known to phosphorylate 
RACK1 at residues Y228 and Y246 which in turn mediates RACK1 association with Src 
[149]. Interestingly, Hic-5 is also tyrosine phosphorylated at residues Y38 and Y60 in 
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Src- dependent manner in response to epidermal growth factor (EGF) stimulation [234]. 
Other stimuli including TGFβ, serum, integrin ligation, LPA and osmotic stress have 
been reported to enhance Hic-5 phosphorylation [170, 174, 176, 234, 235]. Moreover, 
studies in breast cancer cells have shown that Src- mediated Hic-5 phosphorylation is 
required for matrix degradation and invasion [186]. Interestingly, Src is also known to 
phosphorylate and activate MT1-MMP [236] as well as FAK [237, 238]. From previous 
studies we know that blocking Src activity using pharmacological inhibitor inhibits 
capillary morphogenesis and lumen formation in invading ECs [239, 240]. Thus, based 
on our results, we can speculate that pro-angiogenic stimuli would induce Src- mediated 
phosphorylation of RACK1 and Hic-5 to direct sprouting in 3D matrices. However, 
biochemical evidence to confirm a requirement of RACK1 and Hic-5 phosphorylation 
during sprouting is warranted. 
Our data reveal, for the first time, two new protein interactions which point 
towards the possibility of a large macromolecular complex formation between RACK1, 
vimentin, MT1-MMP, FAK and Hic-5. All of these molecules are required for 
angiogenesis and have also been implicated in cancer. MT1-MMP [226, 227, 241-243] 
and FAK [228, 229, 244, 245] have been well distinguished as primary targets for anti-
cancer drugs. Several studies demonstrate up-regulation of vimentin during epithelial to 
mesenchymal transition (EMT) [246] and cancer [247-249]. RACK1 is used as a 
prognostic indicator for breast cancer [166, 167, 250, 251] and has also been reported to 
be up-regulated during human carcinomas [128, 252-256]. Hic-5 has been recently 
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shown to be required for breast cancer cell attachment, motility, invasion, matrix 
degradation, and metastasis [186, 211]. Our data identify RACK1 and Hic-5 to be 
critical regulators of angiogenesis, and help explain their possible roles in tumor 
vascularization, a key step towards tumor growth and progression. Studies in animal 
models designed to test the effect of RACK1 or Hic-5 inhibition on tumor 
vascularization would be highly informative in determining the role of these molecules 
during malignant disease. These experiments would basically involve generation of 
RACK1 or Hic-5 depleted tumor cells using siRNA or shRNA mediated gene silencing 
along with appropriate controls. Injection of tumor cells in immunocompromised 
animals and study of tumor growth rate, metastasis and tumor morphology would 
provide detailed information on the effect of RACK1 or Hic-5 depletion during cancer. 
From our results, we speculate that silencing these molecules would decrease tumor 
progression rate and angiogenesis in tumor microenvironment. Designing small 
molecule inhibitors specific to RACK1 or Hic-5 provides another promising and exciting 
area for future investigation.   
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